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The ubiquitous chromatin opening element (UCOE) derived from the human 
HNRPA2B1-CBX3 housekeeping gene locus (A2UCOE) is able to provide highly 
reproducible and stable expression even from transgenes integrated within extreme 
heterochromatic regions (such as centromeres). The A2UCOE consists of the 
methylation-free CpG island encompassing the dual divergently transcribed 
promoters of HNRPA2B1 and CBX3. The proposed mechanism of A2UCOE function 
is a two-component model: (i) an extended methylation-free CpG island and (ii) dual 
divergent transcription with an inherent chromatin opening capability from the innate 
HNRPA2B1 and CBX3 promoters. Stable expression by the A2UCOE can be 
achieved from either driving transcription directly off the HNRPA2B1 promoter or by 
linkage to a silencing-prone heterologous ubiquitous or tissue specific promoter. 
 
The A2UCOE has been shown to provide highly reproducible and stable transgene 
expression from within lentiviral vectors (LVs) both in vitro and more importantly in 
vivo following ex vivo gene transfer to mouse bone marrow haematopoietic stem cells 
(HSCs). It has recently been shown that efficient and stable expression of transgenes 
from the A2UCOE is at least in part due to its resistance to DNA methylation-







The aim of this project was two-fold. First, to test the two-component model of 
A2UCOE function by evaluating other elements with a similar CpG island - dual 
divergent transcriptional promoter configuration. Second, to dissect the A2UCOE in 
an effort to identify sub-regions that are crucial for its dominant chromatin opening 
activity and thus obtain a minimal fully functional element. This would allow further 
savings of space for therapeutic gene sequences once incorporated within LVs.   
 
Methodology 
Novel candidate UCOEs and A2UCOE sub-fragment-based eGFP reporter gene 
constructs within an LV context are functionally tested by transduction of P19 and F9 
murine embryonic carcinoma cell lines and measurement of stability of expression 
over time both before and after differentiation down neuroectodermal and endodermal 
lineages respectively. Candidates showing encouraging signs of stability of 
expression in P19 and F9 cells would then also be tested for stability of expression in 
murine embryonic stem cells. 
 
 
Results and Conclusions 
The methylation-free CpG island, dual divergently transcribed regions used to test the 
overall two-component model of UCOE function were the native genomic SETD3-
CCNK housekeeping gene pair and the artificially constructed single promoter 
RPS11-HNRPA2B1 combined in a divergent configuration. Linkage of these elements 
in both orientations upstream of the highly silencing prone SFFV-eGFP reporter gene 
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system resulted in significant but only partial protection against silencing compared 
to the fully functional core 1.5A2UCOE-SFFV-eGFP reference. This was the case in 
P19 and F9 cell systems both before and after differentiation. 
 
Various sub-fragments of the A2UCOE region ranging in size from 450-950bp either 
with or without associated promoter activity, were linked upstream of the SFFV-
eGFP cassette and again compared to 1.5A2UCOE-SFFV-eGFP to assess their ability 
to negate transcriptional silencing. The results showed that none of the A2UCOE sub-
fragments tested retained a full UCOE capability. Fragments from the CBX3 first 
intron lacking promoter activity, but with a high CpG content, were particularly 
noteworthy for their total inability to rescue expression from the silencing-prone 
SFFV promoter. A 0.9kb sub-core fragment of the 1.5kb A2UCOE extending over 
both CBX3 and HNRPA2B1 transcriptional start sites was only partially able to negate 
silencing of the linked SFFV promoter. 
 
Analysis of a deletion series from the CBX3 end of a fully functional 2.2kb A2UCOE 
where expression of an eGFP reporter gene is directly driven off the HNRPA2B1 
promoter, revealed a 1.7kb truncation that retained full UCOE activity following 
transduction of P19 and F9 cells in both undifferentiated and differentiated states. A 
further deletion to 1.2kb lacked this capability. This 1.7A2UCOE was also able to 
retain stable expression in murine embryonic stem cells and during differentiation 




In summary, we were able to identify a native (SETD3-CCNK) and construct an 
artificial (RPS11-HNRPA2B1) dual divergent promoter combination with a significant 
but partial UCOE function compared to the fully functional prototypical HNRPA2B1-
CBX3 system. A2UCOE sub-fragments that were CpG rich but devoid of one or both 
of the CBX3 and HNRPA2B1 promoters, were at best only partially capable of 
conferring stability of expression. Lastly, we were able to substantially reduce the 
length of the A2UCOE required for full activity when gene expression is sought 
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Gene therapy can be defined as the treatment of a disease or medical disorder by 
introducing of therapeutic nucleic acid material (DNA, RNA) into living cells. 
This nucleic acid material or therapeutic genes can change a specific gene 
mutation or re-program cell functions to treat a disease. Gene therapy can be 
achieved by viral and non-viral delivery (vector) methods. Viral vectors take 
advantage of the natural infectious properties of viruses whilst non-viral 
methods use DNA-pharmaceutical formulations such as liposomes. 
 
1.1.1. Non-viral gene therapy 
 
Non-viral gene therapy is the concept of introducing naked DNA, RNA and 
oligonucleotides into the cell. Although there are certain advantages of this 
methodology compared with viral methods, such as low host immunogenicity, 
and simple large-scale production, non-viral gene therapy has actually failed in 
most instances to present sufficient delivery and stable expression to be 
competitive to viral delivery. The one condition where non-viral vectors have 
shown some promise is targeting the lung in cystic fibrosis patients 




1.1.2. Viral gene therapy 
 
Viruses are intracellular obligate parasites that evolved as efficient vehicles for 
the transfer of DNA or RNA by infection of target cells. Wild-type viruses 
infect the target cells by introducing their genetic material into the host cell as 
part of their replication cycle. The genetic material of wild-type viruses, takes 
control the target cell normal replication mechanisms to serve the requirements 
of the virus and the target cells in the end follow these orders and produce 
additional copies of virus, causing more and more cells to become infected. This 
process of infection opened the way for viruses to be used as vectors to carry 
desired genetic material into human cells. Additionally, the removal of genetic 
disease-causing viral genes from the vectors and the replacement of these parts 
with genes encoding therapeutic genes of interest showed a viable and safe 
alternative method to common therapeutics, and provided a way forward in the 
field of gene therapy. 
 
Today, a large number of viruses with exclusive characters valuable for gene 
therapy have been identified. This led to the use of recombinant viruses such as 
adenoviruses, adeno-associated viruses, herpes viruses, poxviruses, retroviruses 









Adenoviruses are non-enveloped viruses having a linear double stranded DNA 
genome. Today, over 40 strains of adenovirus have been identified, and most of 
them are known as causing benign respiratory tract infections in humans. 
Adenovirus genetic material normally replicates as an episomal element in host 
cells instead of integration into the host genome. The adenovirus genome is 
approximately 35kb, which in the case of “gutted” vectors can be replaced with 
approximately 30kb foreign DNA (Verma and Somia 1997).  
 
Although, adenoviruses are very efficient at transducing a wide range of target 
cells in vitro and in vivo, and can be produced at high vector titres (>10
11
/ml), 
transgene expression in vivo can be transitory due to the fact that this class of 
virus can elicit a potent immune response, which can limit their therapeutic 




Adeno-associated viruses (AAV) are a non-pathogenic group of human viruses 
that are normally dependent on a helper adenovirus to propagate. They have a 
single stranded DNA genome, consisting of two genes; rep, coding of for 
proteins that control viral replication, structural gene expression and integration 




As in the case of adenoviral vectors, AAV gene therapy vectors have the ability 
to infect both dividing and non-dividing cells. They are retained in an extra 
chromosomal state without recombining into the genome of the host cell. Some 
studies have reported a degree of clinical success with AAV vectors targeting 
the retina in cases of Leber’s Congenital Amaurosis (Bainbridge, Tan et al. 




Retroviruses are viruses characterised by three main features: they have a single 
stranded (ss) RNA genome; possess their own reverse transcriptase enzyme; and 
a virion morphology that consists of two proteinaceous structures and a dense 
core, all surrounded by an envelope structure (Vogt and Simon 1999). 
 
Retroviruses have a lipid bilayer-enveloped particle structure and their ssRNA 
genome can vary from 7 to 11kb in length. Upon cell entry, retroviruses move 
from the cell surface to the nucleus. In the mean time the ssRNA genome is 
retro-transcribed into linear double stranded (ds) DNA by their reverse 
transcriptase enzyme. When dsDNA reaches the nucleus, it integrates into the 
host cell genome to form a structure known as the “provirus” and is passed on 
to daughter cells upon cell division. The proviral genome consists of long 
terminal repeats (LTRs) located at both ends (5’ and 3’) containing various 
components such as the U3 and U5 transcriptional control elements including 
promoters and enhancers (Figure 1.1). The viral LTRs flank the viral genome 
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with the 5’LTR responsible for transcription of the tandem genes encoding 
group-specific antigen (gag) that form the core and structural proteins of the 
matrix and nucleocapsid, polymerase (pol) coding for the reverse transcriptase 
protease and integrase enzymes, and envelope (env), which is a transmembrane 
protein component of the retroviral coat. The other parts of the retroviral 
genome are the packaging signal (psi or ψ) required for the specific packaging 
of the full length viral RNA genome into newly formed virions (Watanabe and 
Temin 1982), and the central polypurine taract (cPPT), which is the site of the 
initiation of positive-strand DNA synthesis during reverse transcription (Rattray 











Figure 1.1. General structure of a retroviral genome. The long terminal 
repeats (LTRs) have sequences needed for the regulation and initiation of 




The Retroviridae are divided in two family groups namely simple and complex 
retroviruses. MLV oncoretroviruses also known as gammaretroviruses are 
examples of the simple class and lentiviruses such as human immunodeficiency 




Lentiviral vectors (LVs), are most frequently based on HIV-1. LVs possess 
advantages over other types of viral vectors based on gammaretroviruses as they 
are capable of transducing non-dividing as well as dividing cells (Naldini, 
Blömer et al. 1996). The property of LVs to transduce non-dividing cells is 
clearly a great asset when targeting either post-mitotic cells or tissues such as 
those of the central nervous system and liver or slow mitotic stem cell 
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populations. In addition, the capability of retroviral/LVs to integrate their 
genetic material into the target cell genome is a clear advantage when targeting 
cells that undergo division, especially stem cells, as this at least decreases and 
possibly avoids the need for their repeated administration. 
 
Another advantage of using LVs is that they are relatively large with a 
manageable capacity of approximately 8kb. Furthermore, by pseudotyping LVs 
with envelope glycoproteins of other viruses during vector production, it is 
possible to redirect their tropism to a broader range of cell types (Bouard, 
Alazard‐Dany et al. 2009). In addition, the use of cell- and tissue-specific gene 
regulatory elements (LCRs, enhancers, promoters) (Lai and Brady 2002, 
Greenberg, Geller et al. 2007, Gascón, Paez-Gomez et al. 2008) can provide a 
restrictive transgene expression pattern and thus reduce the risk of immune 
reactions against the therapeutic product. 
 
There have been enormous improvements in the safety of LVs since they were 
first developed. The wild type viral genes of the first generation (Naldini, 
Blömer et al. 1996) (VSV 1996) and non-essential parts of the second and third 
generation genome have been removed (Loeb, Cordier et al. 1999). This caused 
a lack of a replicative capacity, which has overcome the problem of producing 
infectious particles. Viral production is achieved with a packaging cell line, 
which is transfected with three or four plasmids, across which the sequences to 
make a vector are distributed. In this production system, only a small part of the 
original vector genome remains even across this allocation of components 
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between different plasmids and as such it prevents the possible homologous 
recombination between the plasmids to reconstruct replication-competent 
virions. This is in addition to avoiding the risk of the possible rescuing of the 
vector in HIV-infected individuals. Only the transfer vector sequences, which is 
one of the 3 or 4 transfected plasmids and contains the therapeutic transgene 
cassette, is packaged into virions along with the required proteins for reverse 
transcription and integration of the vector genome into the target cell. The 
remaining viral genes whose products are required for replication lie on the 
helper plasmids that remain within the packaging cell line. 
 
1.1.3. HIV virus 
 
1.1.3.1.HIV genome structure 
 
The wild type HIV genome compromise of two unspliced ssRNA molecules of 
approximately 10 kb length located within a nuclear core enclosed by a 
nucleocapsid and a viral envelope core. 
 
The HIV genome is regularized into the gag, pol, and env gene form (Figure 
1.2). Gag gene roles on encoding the structural proteins, and the pol gene 
provides the enzymes that comes with the ssRNA. The reverse transcriptase 
enzyme performs the reverse transcription of the viral RNA to DNA. The 
integrase enzyme carries out the integration of the proviral DNA into the host 
genome, and protease enzyme regulates the gag/pol disintegration and virion 
maturation (Katz and Skalka 1994). Env roles on encoding the viral envelope 
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part of the virion. 
 
The Wild type HIV-1 has two regulatory genes, tat and rev. These genes are 
necessary for viral replication and gene expression. The protein tat gene 
encoding plays in the activation of the promoter in the HIV LTR so that viral 
RNA is produced efficiently, and Rev interacts with a region of viral RNA 
known as the Rev-responsive element (rre) and promotes the transport of viral 
RNA from the nucleus to the cytoplasm (Pluta and Kacprzak 2009). Although 
HIV-1 holds the retroviral genome organisation, it also has four additional 
accessory genes, vif, vpr, vpu and nef, which play for in vivo replication and 
pathogenesis (Figure 1.2; (Coil and Miller 2004)).  
 
The later researches have focused on the use of the therapeutic vectors raises 
safety concerns as the cytotoxic or cytostatic encoding proteins; vpr induces G2 
cell cycle and nef alters cellular activation pathways. Cell surface molecules 
such as CD4 and the class I major histocompatibility complex are induced by 
nef and vpu. In addition, the accessory genes nef, vif and vpr are integrated into 
viral particles and can improve the immunogenicity of vectors. For those safety 
concerns, lentiviral vectors (LV) are constructed in the absence of these genes, 
which have been shown not to be essential for viral transduction (Delenda 2004, 










Figure 1.2. The wild type HIV-1 genome. A) demonstarates the 2D 
representation of the virus, with the encoding proteins (gp41, p17, p24, p7.,etc.) 
encircling te core containing the viral RNA and reverse transcriptase. The virus 
is mainly composed by three genes (Gag, Pol and Env) encoding the packaging 
and envelope proteins of the virus flanked by the two LTRs, as shown in B) 




1.1.3.2. HIV life cycle 
 
The HIV life cycle starts by binding of the viral envelope glycoprotein gp120 to 
a CD4 receptor and a secondary receptor on the cell surface after which 
conformational changes in the non-covalently associated gp41 subunit releases 
free energy sufficient to endorse fusion of the viral particle envelope with the 
cell membrane. The viral core is then transferred into the cell cytoplasm and 
reverse transcription of the viral RNA takes place. The reverse transcription unit 
(RTC) is then moved towards the nucleus by the cellular proteins. When reverse 
transcription cycle is finished and the provirus and several viral proteins 
formed, the pre-integration complex (PIC) is then transferred into the nucleus 
by the cellular proteins. After the integration to the cell genome, transcription is 
carried out by RNAP II and enhanced by the viral protein Tat. Unspliced and 
partially spliced transcripts are stabilised by the viral protein Rev (Pluta and 
Kacprzak 2009). 
 
1.1.4. Development of lentiviral vectors 
 
For safety concerns, reducing the risk associated with producing and use of LVs 
in gene therapy, all non-essential genes coding for accessory proteins and 
responsible for virulence, should be removed from the vector sequence. 
Moreover, the vector genome is typically broken up into several parts with 
limited sequence overlap to minimize the possibility of independent 
recombination to form wild type viral particles and vector mobilization. The 
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genes necessary for lentiviral vector production are therefore divided on 
different plasmids that are co-transfected into HEK293T cells together as a 
complex aggregated with the help of a transfection agent (see Materials and 
Methods section). Therefore, the generation system typically consists of 
packaging expression cassettes (helper), a vector cassette (transfer vector) and 
an envelope expression cassette (Figure 1.3). 
 
Figure 1.3. Lentiviral vector production protocol by 293T cells. As in 
oncoretroviral vectors, the viral genes gag, pol and env are replaced by the 
transgene of interest. The LTR and the packaging signal ψ are maintained for 
vector amplification and packaging. Of the lentiviral accessory proteins, only 
the rev responsive element (RRE) is maintained as an additional cis-acting 
sequence required for the nuclear export of unspliced and single-spliced viral 
RNAs in the presence of the Rev protein. Rev is expressed by one of the three 
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packaging constructs. The two others encode the Gag/Pol or the Env proteins, 
respectively. (Image taken from http://www.addgene.org/) 
1.1.5. Development of SIN vectors 
 
The risks associated with viral recombination can happen at the DNA level, 
particularly during the production of co-transfected plasmids, between 
transfected plasmids or between the proviral vector and a homologous 
chromosomal sequence in the target cell. Therefore, the possibility of full-length 
LV transcription and propagation after integration into the target cell needs to 
be addressed. It is possible for the integrated proviral LV to be mobilized by 
replication competent virus; such as, if the transduced cell were later infected 
with wild type HIV-1. In addition, there is also the possibility of the unusual 
expression of host genes by LTR that are adjacent to the site of LV integration. 
These concerns led to the development self-inactivating (SIN) LVs. 
 
The first SIN retroviral vectors were prepared in an MLV- based vector (Yu, 
Nash et al. 1986, Yee, Pasi et al. 1999). The first vector was produced with a 
deletion of 299bp in the U3 region, containing the enhancer and promoter 
CAAT box unit with the second having the additional deletion of the TATA 
box. Nevertheless, retroviral vectors exhibit weak polyadenylation sites and 
deletion of U3 to generate SIN vectors increased the chances of read-through 
thus augmenting the potential for insertional (Furger, Monks et al. 2001, Zaiss, 
Son et al. 2002). The same method was used later in LVs design by Miyoshi and 
colleagues (Miyoshi, Blömer et al. 1998) by further deletion of a 133bp section 
from the U3 region of the 3‟ LTR, which removed the TATA box and other 
transcription factor binding sites, resulting in transcriptional inactivation of the 
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proviral LTR in targeted cells, both in vitro and in vivo. This modification 
demonstrated no changes in the viral transcript levels of the producer cells, and 
no major reduction in viral titre. In addition, expression of the transgene in vivo 
in both neurons and retinal cells was improved with this SIN vector due to the 
removal of transcriptional interference from the HIV-1 LTR promoter/enhancer 
by this research. The study also reported a further deletion of the 
enhancer/promoter sequences in the U3 region of the 3‟ LTR (120-40bp U3). 
 
Additional success was obtained by Zufferey and colleagues (Zufferey, Donello 
et al. 1999) with a deletion of up to 400bp of the 3’LTR U3 region. Once more, 
the vector production was neither decreased nor was transduction efficiency 
lesser in vitro or in vivo. In addition, it has been shown that in SIN vector 
transduced cells that were subsequently infected with wild type HIV-I, the 
vector was not mobilised (Poccia, Battistini et al. 1999). 
 
By the development of SIN LV, promoter interference was extensively reduced 
and this also provided a potential safety advantage over traditional retroviral 
vectors. In particular, upon reverse transcription, during the step of viral 
replication, the U3 region will be duplicated in both LTRs, thus both LTRs are 
inactivated leaving only the very 5‟ end of the U3 for integrase detection and 
function. Expression of the transgene will thus be restricted from an internal 
promoter. 
 
Transcription of full-length viral vector RNA transcripts is noticeably reduced 
in cells transduced with a SIN vector when the LTR deletion is sufficient. This 
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also decreases the risk of generating replication competent retrovirus and there 
is a rather incomplete U3 enhancer sequence in the proviral 5’LTR interfering 
with internal, heterologous promoters. Moreover, it provides additional safety 
advantages, as it is more difficult to re-generate a wild-type parental retrovirus 
via recombination. With the deletion of the viral transcriptional elements from 
the vector, synthesis of vector RNA will depend on site of integration (Kappes 
and Wu 2001). 
 
Additionally, the SIN vector design avoids transcriptional interference by the 
promoter/enhancer units in the host genome, reducing the possibility of 
insertional activation and mutagenesis of adjacent coding sequences (such as 
oncogenes) either by transcription from the 3’LTR at the site of vector 
integration or LTR enhancer activation of a host gene promoter. To improve 
biosafety, the use of SIN vectors also provides two additional advantages; 
elimination of transcriptional interference by the LTR promoter, and the 
possibility to create tissue-specific and inducible vectors via appropriate internal 
promoters, which would be not easy in the presence of non-specific 
transcription from the LTR promoter (Kappes and Wu 2001). 
 
 
1.2.Success in clinical trials using viral vectors 
 
1.2.1. Trials of gene therapy for X-linked severe combined immunodeficiency 
(SCID-X1) 
 
X-linked severe combined immunodeficiency disease (SCID-X1) is an inherited 
disease with absent T lymphocyte function, due to lack of the common cytokine 
32 
 
receptor -chain (c; IL2RG). In 2000, a successful treatment of 2 children 
suffering from SCID-X1 was achieved by the transduction of a normal 
functioning copy of the IL2RG cDNA in patient bone marrow HSC using a 
gammaretroviral vector based on murine Maloney leukaemia virus by an ex vivo 
delivery method (Cavazzana-Calvo, Hacein-Bey et al. 2000, Hacein-Bey-Abina, 
Le Deist et al. 2002). A similar and equally successful gene therapy approach 
for SCID-X1 was also carried out in London (Gaspar, Parsley et al. 2004). 
During the years following treatment, results demonstrated no indication of 
replication competent retrovirus in the patients. All patients responded well to 
the treatment with restoration of immune system function. However, of the 20 
patients treated, 5 subsequently developed a lymphoproliferative, leukaemia-
type condition associated with the gene therapy itself. The analysis of these 
cases found that the root cause was gammaretrovirus-induced insertional 
mutagenesis leading to upregulation of proto-oncogene expression, particularly 
LMO2 (Hacein-Bey-Abina, Von Kalle et al. 2003, Howe, Mansour et al. 2008, 
Escors and Breckpot 2010).  
 
1.2.2. Gene therapy for chronic granulomatous disease (CGD) 
 
A treatment for X-linked chronic granulomatosis disease (X-CGD) was reported 
in 2006, using a gammaretroviral vector carrying the therapeutic gp91phox 
cDNA under control of the SFFV promoter-enhancer element within the vector 
LTR and targeting bone marrow HSC (Ott, Schmidt et al. 2006). A successful 
outcome was initially observed in both adult male patients treated in this trial 
using an ex vivo procedure. The two patients used in this treatment showed a 
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high level of corrected leukocytes in peripheral blood (~20%) within the first 
months after treatment, which reached up to 80% over the first year.  However, 
a benign form of myelodysplasia, a pre-leukemic condition was then seen in the 
patients by the insertion within and subsequent activation of the MDS1-EVI1, 
PRDM16 and SETBP1 genes (Stein, Ott et al. 2010) via the vector SFFV 
enhancer. Crucially, although neutrophil counts were observed to be maintained 
at normal levels, therapeutic transgene function was lost in both cases leading to 
death of one of the patients from severe bacterial sepsis after colon perforation 
27 months after gene therapy. Molecular analysis showed that in both patients 
the SFFV promoter (but not enhancer) driving expression of the therapeutic 
gp91phox had become methylated and thus inactivated leading ultimately to 
treatment failure (Ott, Schmidt et al. 2006, Stein, Ott et al. 2010). A possible 
solution to this problem of transgene silencing and treatment failure is to 
employ therapeutic gene cassettes whose expression is augmented with the 
ubiquitous chromatin opening element (UCOE) from the human HNRPA2B1-
CBX3 locus (Brendel, Müller-Kuller et al. 2011).  
 
1.2.3. Gene therapy for Leber’s Congenital Amaurosis (LCA) 
 
A number of clinical trials with encouraging outcomes have targeted the genetic 
eye disorder Leber’s Congenital Amaurosis (LCA). Around 10% of LCA 
patients are defective in RPE65, whose protein product is required for normal 
retinal cycling of vitamin A. Thus in the reported trials AAV vectors were 
employed to deliver in vivo a correctly functioning copy of the RPE65 cDNA to 
the retinal pigment epithelia cells (Bainbridge, Tan et al. 2006, Alexander, 
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Linde-Zwirble et al. 2007). The results from three young adult patients with 
severe retinal dystrophy resulted in one showing a marked improvement in 
retinal function and visual mobility in low light conditions (Bainbridge, Tan et 
al. 2006).  
 
In a second gene therapy trial for LCA using an AAV-RPE65 vector also 
showed signs of improvement in visual perception in all three patients treated 
(Maguire, Simonelli et al. 2008). In addition, the safety and efficacy of the 
vector has continued through to at least 1.5 years post-injection (Simonelli, 
Maguire et al. 2009). 
 
1.2.4. First human gene therapy trials using lentiviral vectors – gene therapy for 
X-linked adrenoleukodystrophy (X-ALD) and metachromatic 
leukodystrophy (MLD) 
 
The first clinical therapy using a lentiviral vector for an inherited disease 
targeted X-linked adrenoleukodystrophy (X-ALD) via an ex vivo HSC approach 
(Cartier, Hacein-Bey-Abina et al. 2009). X-ALD is a brain demyelinating 
disease caused by mutation of ABCD1 encoding the ALD protein that is an 
adenosine triphosphate binding cassette transporter in the membrane of 
peroxisomes. The LV used in this treatment expressed a wild-type ABCD1 
cDNA under the control of the myeloproliferatuve sarcoma virus promoter-
enhancer (MDN) and was used to genetically correct autologous cytokine-
mobilised peripheral blood CD34
+
 cells ex vivo. In this first trial two young 
patients were transplanted with these autologous corrected HSCs following pre-
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transplant conditioning with myeloablative doses of busulfan and 
cyclophosphamide. The results showed that this therapeutic approach stopped 
progression of the disease with the same efficacy as transplant of allogeneic 
bone marrow HSC from a matched donor. Thus, this study demonstrated that 
LVs could mediate important improvements of gene transfer into human HSCs. 
 
Following on from this success with X-ALD, a similar procedure was employed 
to treat patients with metachromatic leukodystrophy (MLD; (Biffi, Montini et 
al. 2013)). MLD is an autosomal recessive inherited, lysosomal storage disease 
condition. It is caused by mutations in ARSA gene giving rise to deficiency of 
arylsulfatase A. This in turn results in accumulation of the enzyme substrate 
sulfatide within numerous cell types namely oligodendrocytes, microglia, and 
certain neurons of the central nervous system, and Schwann cells and 
macrophages of the peripheral nervous system. The build-up of sulfatide gives 
rise to widespread demyelination and neurodegeneration coupled with severe 
progressive motor and cognitive impairment. The condition is fatal within a few 
years of disease onset. 
 
An LV containing an ARSA cDNA under control of the phosphoglycerate 
kinase promoter (PGK.ARSA.LV) was used in an ex vivo bone marrow HSC 
gene therapy procedure to treat a total of 9 patients (6 infants, 3 older) who also 
underwent full myeloablative conditioning with busulfan prior to autologous 
gene corrected HSC transplantation. Polyclonal engraftment in all peripheral 
blood lineages was obtained in all cases with stable ARSA enzyme activity 
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observed including within the CNS. Overall, a marked improvement in clinical 
condition was observed in all cases including decline in peripheral neuropathy 
(proportional to level of engraftment), total rescue of motor ability over time 




Gene silencing is a generic term that includes a wide range of related topics. A 
frequent effect observed with embryonic carcinoma (and other) cells transduced 
with retroviral vectors is transcriptional silencing shortly after infection (Teich, 
Weiss et al. 1977, Teich, Weiss et al. 1977, Speers, Gautsch et al. 1980, Ellis 
2005). Another problem that can also occur following retroviral vector 
transduction is variegation, in which genetically identical sister cells containing 
the same provirus may either express or be silenced (Yao, Sukonnik et al. 
2004). So this situation refers to the progressive silencing of an initially 
expressed provirus during long-term culture or differentiation (Laker, Meyer et 
al. 1998). 
 
1.4.Silencing of lentiviral vectors 
 
LVs were first developed by Naldini et al. in 1996, with subsequent 
improvements in vector design and packaging systems (Zufferey, Dull et al. 
1998). Subsequently there has been a large accumulation of data concerning 
gene silencing of self-inactivating (SIN) LVs. Transgene silencing can be 
through one of two mechanisms. The first is through integration within a region 
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of heterochromatin. Second, de novo methylation of the transgene promoter can 
take place despite the fact that gammaretroviral and lentiviral vectors 
preferentially integrate within active, transcriptionally permissive regions of the 
genome (Antoniou, Skipper et al. 2013). 
 
For example, a SIN PGK-EGFP LV was shown to allow the non-selective 
isolation of mouse ES cells transduced at a single proviral copy (Yao, Sukonnik 
et al. 2004). The PGK-EGFP LV in the ES cell lines obtained was silent, 
variegated or low expressing, and in addition, subject to extinction during 
differentiation to embryoid bodies. Moreover, chromatin immunoprecipitation 
experiments showed that silent chromatin composed of bound histone H1 and 
deacetylated histone H3 preferentially forms on the HIV-1 LV sequences to 
silence the EGFP reporter gene, similar to the silent chromatin that forms on 
gammaretroviral vectors. These findings establish that SIN LVs can exhibit all 
aspects of gammaretroviral gene silencing in ES cells, and the same chromatin 
features are observed with silenced LVs (Ellis 2005).  
 
1.5.Ubiquitous Chromatin Opening Elements (UCOEs) 
 
When producing a therapeutic protein, a number of different factors affect the 
process. The level of RNA expression depends on the design of the vector used. 
Many mammalian expression vectors are commercially available, which 
incorporate different regulatory elements to maximize the expression of the 
therapeutic protein including promoters and enhancers, and post-transcriptional 
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elements such as the woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE). Moreover, getting reliable and stable transgene expression in 
mammalian cells is another major challenge. The problem of mammalian vector 
system inadequacy to express proteins in a stable manner can frequently result 
in silencing of the exogenous gene usually by methylation of CpG DNA 
sequences and histone deacetylation leading to chromatin condensation (Razin 
1998, Fuks 2005). The discovery of ubiquitous chromatin opening elements 
(UCOEs) that are able to confer resistance to heterochromatin and DNA 
methylation-mediated silencing has led to the incorporation of these elements 
into expression vectors including LVs (Benton, Chen et al. 2002, Benton, Chen 
et al. 2002, Ellis 2005, Zhang, Thornhill et al. 2007, Zhang, Frost et al. 2010). 
 
UCOEs are currently defined as methylation-free CpG island elements that 
extend over at least one and preferably two closely spaced, dual divergently 
transcribed promoters, which are derived from housekeeping gene loci 
(Antoniou, Harland et al. 2003, Antoniou, Harland et al. 2003, Williams, 
Mustoe et al. 2005). The prototypical UCOEs are those derived from the human 
TBP-PSMB1 and HNRPA2B1-CBX3 housekeeping gene loci with both 
consisting of a methylation-free CpG island spanning dual, divergently 
transcribed promoters (Figure 1.4; (Antoniou, Harland et al. 2003, Williams, 









Figure 1.4. Illustration of the closely spaced, dual divergently transcribed 
promoter regions of the human CBX3-HNRPA2B1 and TBP-PSMB1 loci 
first identified to have UCOE function. Black boxes denote exons. Horizontal 
arrows show direction of transcription. CpG dinuclotide density maps are 
shown below the genomic structural illustration. 
 
Using assays in stably transfected cell lines with plasmid vectors, both of these 
elements were shown to be capable of conferring reproducible and stable 
expression even from within centromeric transgene integration sites 
demonstrating their dominant chromatin opening capability (Antoniou, Harland 
et al. 2003). The UCOE from the HNRPA2B1-CBX3 locus (A2UCOE; Figure 
1.5) is able to provide stable transgene expression by transcription from the 
innate HNRPA2B1 promoter (Antoniou, Harland et al. 2003). In addition, the 
A2UCOE can confer stable expression on linked silencing-prone promoters 
such as CMV (Williams, Mustoe et al. 2005). The proposed mechanism by 
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which the A2UCOE can provide stable transgene expression is a two-
component model; an extended region of methylation-free DNA coupled with 
divergent transcription with inherent chromatin remodelling (Allen and 
Antoniou 2007). 
         
In more recent years A2UCOE-regulated transgenes have been successfully 
integrated into LVs. As seen in stably transfected cell lines with plasmid vectors 
(Antoniou, Harland et al. 2003, Williams, Mustoe et al. 2005), the A2UCOE 
can provide stable expression either directly from the innate HNRPA2B1 
promoter (Zhang, Thornhill et al. 2007) or by linkage upstream of ubiquitous 
(Zhang, Thornhill et al. 2007, Pfaff, Lachmann et al. 2013) or tissue-specific 
(Brendel, Müller-Kuller et al. 2012) promoters. Stability of expression is 
observed not only in tissue culture but more importantly in HSCs and all their 
differentiated progeny in vivo (Zhang, Thornhill et al. 2007, Zhang, Frost et al. 
2010, Brendel, Müller-Kuller et al. 2012).  In addition, more recently A2UCOE-
augmented cassettes in LVs have been shown to provide stable expression in 
embryonic and induced pluripotent stem cells and differentiated progeny 
representative of all three germ layers (Pfaff, Lachmann et al. 2013, 
Ackermann, Lachmann et al. 2014). A2UCOE resistance to silencing within 
LVs is at least in large part due to its ability to negate promoter DNA 
methylation (Zhang, Frost et al. 2010, Brendel, Müller-Kuller et al. 2012, Pfaff, 




Figure 1.5. Illustration of the relative positions of the A2UCOE region 
sub-fragments shown to possess full UCOE activity. Upper panel: CpG 
density map and methylation-free CpG island. Middle panel: Positions of the 
two alternative first exons of CBX3 (orange arrows) and the first exon of 
HNRPA2B1 (red arrow). Lower panel: positions of the fully functional 
A2UCOE sub-region fragments. 2.2UCOE: 2.2kb element used to drive 
expression from hnrpa2b1 promoter. 1.5UCOE: 1.5kb element used to link 
upstream of heterologous promoters. 12UCOE: a 1.2kb sub-fragment of the 
1.5UCOE element with a deletion of 300bp from the hnrpa2b1 end to match 
that in the 2.2UCOE fragment. 
 
 
These properties of the A2UCOE suggest that it can potentially play a 
significant role in gene therapy LVs for a number of reasons. First, the 
A2UCOE provides stable transgene expression in the absence of an enhancer 
element, which reduces the possible risk of insertional mutagenesis and thus 
providing a higher safety profile. Second, A2UCOE-LVs are resistant to 
integration site position-specific reduction in expression of both the inherent 
A2UCOE and linked ubiquitous and tissue-specific heterologous promoters 
(Zhang, Thornhill et al. 2007, Zhang, Frost et al. 2010). 
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We and others have sought to identify any A2UCOE region sub-fragments 
that retain their resistance to transcriptional silencing. Prior to the 
commencement of this study, a 2.2kb A2UCOE fragment had been identified 
as the minimum required to drive stable expression from the innate 
HNRPA2B1 promoter (Antoniou, Harland et al. 2003). In addition, a core 
1.5kb (Williams, Mustoe et al. 2005, Brendel, Müller-Kuller et al. 2012) or 
1.2kb (Zhang, Frost et al. 2010) fragment from the A2UCOE spanning the 
transcriptional start sites of both HNRPA2B1 and CBX3, were found to 
stabilise expression of linked heterologous promoters (Figure 1.5). 
 
Recently, a 700bp sub-fragment of the 1.5kb A2UCOE extending over the 
CBX3 promoter and alternative first exons alone has been claimed to confer at 
least partial resistance to silencing from both its innate albeit very weak CBX3 
promoter and when linked to heterologous EF1 and MRP8 promoters 
(Brendel, Müller-Kuller et al. 2011). All these A2UCOE fragments function 
(Brendel, Müller-Kuller et al. 2011) through a mechanism that negates DNA 
methylation-mediation silencing.  
 
Interestingly, both the 1.5kb and 1.2kb A2UCOE fragments (Figure 1.5) in an 
LV context targeting HSCs and embryonic stem cells were found to confer 
stability and specificity of expression on linked promoters in an orientation-
dependent manner; that is, with the CBX3 end of the element juxtaposed next to 
the downstream heterologous promoter (Zhang, Frost et al. 2010, Brendel, 
Müller-Kuller et al. 2011, Brendel, Müller-Kuller et al. 2011). Furthermore, it 
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has also been reported that a promoter-less sub-fragment of the A2UCOE 
derived from the region downstream of the CBX3 promoter within the first 
intron of this gene, is also capable of conferring stability on a linked 





Given the current status of the field surrounding UCOEs, the overall objectives 
of this project were to functionally test current model of the UCOE mechanism 
of action, namely the requirement for dual divergent transcription from within 
an extended DNA methylation-free CpG island region. In order to address this 
we planned to: 
1. Test the UCOE concept for its generality by identifying novel elements 
from housekeeping gene loci with a dual divergently transcribed promoter 
configuration but which would also function in an orientation independent 
manner. 
2. Functionally dissect the A2UCOE region to identify sub-fragments that 
retain a full transcriptional stabilising function but which (i) potentially lack 
one or both of the HNRPA2B1 and CBX3 promoters and (ii) reduce the size 
of the associated CpG island.   
All test constructs would be within an LV context and functional analysis by 
transduction and expression analysis within murine embryonic teratocarcinoma 
P19 and F9 cells as they are a proven model for gene silencing (Zhang, Frost et 
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al. 2010). Studies would be extended to those previously conducted by 
investigating stability of expression in not only undifferentiated cells but also in 
P19 cells induced to undergo differentiation into neurons and F9 cells that had 
undergone endodermal differentiation (Jones-Villeneuve, McBURNEY et al. 
1982, Yoon, Lee et al. 2009). Finally, novel candidate UCOE constructs that 
gave encouraging results in P19 and F9 cell assays would be tested within a 






























2.1.1. Commercial kits 
 
EndoFree Plasmid Maxi kit (QIAGEN®, Hilden, Germany)  
HighSpeed Plasmid Maxi Kit (QIAGEN®) 
QIAprep Spin Miniprep kit (QIAGEN®) 
 QIAzol Lysis reagent (QIAGEN®)  




Avanti J-20 Centrifuge (Beckman Coulter, High Wycombe, UK)  
Becton Dickinson FACS Calibur (Franklin Lakes, NJ, USA)  
BioDoc-It UV transilluminator system (Ultra-Violet products- UVP Ltd., Upland, 
CA, USA)  
Biofuge Pico microfuge (SORVALL ®, New Castle, Delaware, USA) 
BioPhotometer (Eppendorf, Hamburg, Germany)  
Centrifuge Universal Legend RT (SORVALL ®)  
Dyad thermocycler (MJ Research Inc., St Bruno (Quebec), Canada)  
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Flourescence light Microscope, Eclipse TS100 (Nikon, Melville, NY, USA)  
Light Microscope, TM (Nikon)  
Micro Centrifuge Pico Biofuge (SORVALL ®)  
Multitron shaking incubator (Infors AG, Bottmingen/Basel, Switzerland)  
Nano-Drop 1000D ((Thermo Fisher Scientific, Loughborough, UK)  
Shaking Multitron Incubator (Infors AG)  
Thermanox® coverslips (Nalge Nunc Int. Penfield, New York, USA)  
UV transilluminator (UVP Ltd)  
 
2.1.3. General chemicals and reagents 
 
2.1.3.1.General chemicals and reagents used in cloning procedures 
 
Ampicillin (Sigma-Aldrich, St.Louis, Missouri, USA)  
Bovine serum albumin (Sigma-Aldrich)  
DEPC treated water (Life Technologies Ltd, Paisley, UK)  
DNA Rehydration Solution (Promega) 
Ethanol (BDH Merck Ltd., Poole Dorset, UK)  
Ethidium bromide (Sigma-Aldrich)  
Glycerol (Sigma-Aldrich)  
Isopropanol (BDH Merck Ltd.) 
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MgCl2, 25mM (Promega)  
NEB buffer 1 (NEB®)  
NEB buffer 2 (NEB®)  
NEB buffer 3 (NEB®)  
NEB buffer 4 (NEB®)  
Phenol (Sigma-Aldrich)  
Phenol: chloroform : isoamyl Alcohol 25 : 24 : 1, v/v (Life Technologies Ltd, 
Paisley, UK)  
Restriction endonucleases: (NEB®) 
Taq Polymerase (Promega)  
Tris Base (Sigma-Aldrich)  
TE buffer solution (Life Technologies Ltd, Paisley, UK)  
Tris Base (Sigma-Aldrich)  
Tris-HCl (BDH Merck Ltd.)  
Tween-20 (Sigma-Aldrich)  
Deoxynucelotide triphosphates (dNTPs), 100mM:  (GE Healthcare Bio-Science 
Corp., Chalfont St. Giles, UK) 
 
2.1.3.2.Reagents used in tissue culture experiments 
 
 
Dimethyl sulphoxide – DMSO (Sigma-Aldrich)  
Fetal calf serum (PAA laboratories Ltd, Somerset, UK)  
Dulbecco’s Modified Eagle’s Medium (DMEM) + Glutamax (PAA)  
Formaldahyde –PFA (Sigma-Aldrich) Optimem® (Life Technologies Ltd)  
Phosphate buffered saline (PBS) (Sigma-Aldrich)  
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Phosphate buffered saline + Calcium and Magnesium (PBS +) (Sigma-Aldrich) 
Polyethylenemine (PEI) (Sigma-Aldrich)  
Polybrene (Sigma-Aldrich)  
Tripsin TrypLE express (Life Technologies Ltd)  
Trypan blue (Sigma-Aldrich) 
 
2.1.4. Bacterial strains 
 
DH5α Chemically competent E.coli (InvitrogenTM)  
GeneHogs Electrocompetent E.coli (InvitrogenTM)  
TOP10 One Shot® Electrocompetent E.coli (InvitrogenTM)  
XL10 GOLD chemically competent E.coli (Stratagene®) 
 
2.1.5. Prepared solutions 
 
      All general laboratory reagents were minimally of Analar Grade. 
 
Luria Bertani (LB) medium: 10 g Tryptone, 5 g Yeast extract and 10 g NaCl were     
dissolved in 1 litre of distilled and deionized water, and then autoclaved on liquid 
cycle for 20 min at 15 psi. The solution was then allowed to cool to 55°C, and 
made 50 g/mL with Ampicillin. The medium was then stored at 4°C. 
 
LB agar plates: 20 g agar per litre of LB broth. LB broth or LB agar media were 
supplemented with 100 mg ampicillin per litre for the production of transformed 




TE buffer – 10x (Tris-EDTA buffer): 
14 g EDTA (electrophoresis grade) (Sigma-Aldrich) plus 30 g Tris base (Sigma-
Aldrich) made up to 1 litre with ddH20, pH to 8 with HCl. 
200 mM methanol (BDH Merck Ltd) in ddH20.  
3M Sodium acetate adjusted to pH5.2 with glacial acetic acid, and sterilised by 
autoclaving. 
50x Tris-Acetate-EDTA (TAE) 50x electrophoresis buffer: 
242 g  Tris base (electrophoresis grade) (BDH Merck Ltd), 57.1 mL glacial acetic 
acid (BDH Merck Ltd) and 100 mL 0.5M EDTA (pH 8) made up to 1L with 















2.2.1. Bacterial cultures 
 
Commercially available competent E coli DH5α (Life Technologies Ltd) was 
used for plasmid transformation in accordance with the manufacturer’s 
instructions.  
Standard aseptic techniques were used in bacteria handling. All cultures were 
carried at 37°C for approximately 16 hours. A shaking incubator set at 180-
200rpm was use for liquid cultures. Solid cultures on petri dishes and liquid 
cultures in universal tubes were kept at 4°C for a short period of time 
(maximum two weeks). A 20%v/v glycerol stock of overnight cultures of clones 
colonies containing plasmids were stored at -80°C. 
 
2.2.2. Plasmid production 
 
Standard methods were used to prepare and store bacteria containing plasmids 
harbouring cloned genes. Bacterial stocks were streaked onto agar plates with 
100 μg/mL ampicillin and grown overnight at 37ºC. Single colonies were 
subsequently picked and used to inoculate liquid cultures of LB medium 
containing 100 μg/mL ampicillin. Small scale, mini-prep cultures were of 5ml 
and large-scale maxi-prep cultures were 200-500 mL in volume. Cultures were 
expanded at 37ºC in a shaking incubator overnight. Plasmid extraction from 
mini-prep and maxi-prep cultures was performed using the appropriate Qiagen 
kit and eluted in TE buffer as per the manufacturer’s protocols. Concentrations 
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of DNA were then determined using a NanoDrop 1000 Spectrophotometer and 
stored at -20ºC.  
 
2.2.3. Gel electrophoresis of DNA fragments 
 
Standard electrophoresis in 0.8-2% agarose gels at 4-200V with 1x TAE buffer 
were used to resolve and analyse DNA fragments from restriction enzyme 
digests.  
Gels and tank buffer contained 0.005% ethidium bromide for UV visualisation 
of DNA bands. The size of DNA fragments was estimated by comparison to 
100bp and 1kb commercially available size ladders (NEB). 
 
2.2.4. Restriction enzyme digestion analysis of plasmid DNA 
 
Digests were performed in reaction mixtures containing:  
1-40 μg DNA, depending on individual experimental requirements,  
10% NEB buffer (NEB Buffer 1 – 4, as appropriate for the enzymes),  
10% 10x BSA (if required by any enzyme),  
1 unit/μg DNA of appropriate restriction endonuclease(s), 
made up to the required volume in ddH2O such that the restriction enzyme 




2.2.5. Lentiviral vector production and quantification 
 
2.2.5.1.Transfection of virus producer cells 
 
Human embryonic kidney 293T (HEK293T) cells were maintained and 
manipulated in DMEM medium supplemented with 10% fetal calf serum (FCS), 
1% 200 mM L-glutamine (Life Technologies Ltd) and 10 μg/mL each of 
penicillin and streptomycin (Life Technologies Ltd) at 37
0
C and 5% CO2 
atmosphere. 
T162 flasks (Corning, Flintshire, UK) were seeded with 2x10
7
 HEK293T cells 
such that the cultures were 80-90% confluent at the time of transfection. The 
following amounts of DNA were added to 5 mL of Optimem (Life 
Technologies Ltd) per T162 flask and before being filtered through a 0.2 μm 
acetate membrane syringe filter (Thermo Scientific UK):  
Vector construct: 50 μg  
Envelope plasmid (pVSV-G): 17.5 μg  
Packaging plasmid (p8.74): 32.5 μg  
A 1μL aliquot of a 10mM stock of PEI was also added to 5mL of Optimem and 
likewise filtered through a 0.2μm filter. DNA and PEI solutions were then 
mixed in a 1:1 ratio and incubated at room temperature for 20 minutes. The 
cells were washed once with 10 mL Optimem and the 10 mL of PEI/DNA 
mixture was then added per T162 flask. The cells were then incubated for 4 
hours followed by replacement of the transfection medium with 25 mL of 
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complete HEK293T DMEM culture media. The media was likewise replaced 
again 24 hours later.  
 
2.2.5.2.Harvesting of lentiviral vector particles 
 
At 48 hours post-transfection the medium was harvested and replaced with 25 
mL fresh DMEM so that virus-containing culture supernatant could be 
harvested for a second time at 72 hours. The harvested medium was filtered into 
50 mL Falcon tubes through a 0.2 μm filter and then centrifuged at 4ºC for 24 
hours at 3000xg. The supernatant was then removed by decantation and the 
tubes inverted onto absorbent tissue to drain the remaining fluid. A 50 μL 
aliquot of Optimem was then added to the viral pellet, which was incubated on 
ice for 20 minutes, taking care that the fluid level in the tubes was over the 
pellet’s location. The viral pellet was then resuspended in the Optimem by 
repeated gentle pipetting. Aliquots of 5-30 μL were then made and stored at -
80C.  
 
2.2.5.3.Viral vector titration 
 
For each viral harvest, 6 wells of a 24-well plate were seeded with 1-2x10
5
 
HEK293T cells, allowed to settle for 4 hours and transduced with serial 
dilutions of concentrated viral stock in order to achieve a range of multiplicity 
of infections (MOI) between 1.0 and 1x10
-5
 times that obtainable from 1 µL of 
the virus stock. Specifically, 1μL of viral particle suspension, which had been 
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frozen and thawed once, was added to 2ml of medium in one well; from the 
remaining stock, 1/10 serial dilutions were then carried out, such that additional 








µL of stock. To 
the 1 mL of medium in each well, a further 1mL of media was added containing 
16 μg/mL of polybrene to give a final concentration of 8μg/mL. The sixth well 
was left untransduced to include as a negative control. Calculation of the MOI 
of 1 mL of stock was then possible by analysis via flow cytometry to discover 
what percentage of the HEK293T cells in a given well were transduced by the 
dilution applied and scaling up as appropriate.  
 
2.2.6. Cell harvesting for flow cytometry analysis 
 
Adherent cells were detached by the application of Tryple Red reagent (Life 
Technologies Ltd) after washing cells with PBS and subsequent neutralisation 
of the Tryple Red with serum-containing medium. Cells were then transferred to 
14 mL or 5 mL tubes and centrifuged for 5 minutes at 1000rpm. The 
supernatant was then removed and the cell pellet resuspended in desired 
medium and volume for further manipulation. In the case of analysis by flow 
cytometry, the pellet was resuspended by adding 1 mL of 4% formaldehyde in 
PBS to fix cells and shaking the tube vigorously; samples were then stored at 
4
0





2.2.7. Quantification of viral titre by flow cytometry 
 
Samples of at least 2x10
5
 fixed cells were analysed for GFP fluorescence by 
flow cytometry. Only live cells within the total cell population were considered 
via analysis of size (measured by forward scatter) versus granularity (measured 
by side scatter) and then detecting light emission at 525 nm (in the colour 
spectrum range FL1) versus light emission at 575 nm (in the colour spectrum 
range FL2) with the aid of control untransduced cells to gate for positive GFP 
signal. This provides a measure of the percentage of cells in the sample that 
were both alive and expressing GFP. The percentage of GFP positive cells in 
each sample was related to the concentration of virus that the sample had 
received and scaled up to give the number of cells transduced by that amount of 
viral stock, thereby permitting the calculation of MOI.  
 
Values of between 1% and 20% were preferred for this calculation, as samples 
with over 20% GFP positive cells were likely to harbour more than one 
integration event per cell and thus cause the underestimation of viral titre, 
whereas those showing less than 1% expressing GFP at detectable levels were 
not useful due to being too likely to be distorted by background noise. 
 
2.2.8. Maintenance and differentiation of P19 cells 
 
Murine embryonic carcinoma P19 cells  were maintained and manipulated in 
Dulbecco’s modified Eagle’s medium (DMEM; GE Healthcare Life Sciences) 
supplemented with 2 mM L-glutamine (Life Technologies Ltd), 1% non-
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essential amino acids (Life Technologies Ltd), 10% fetal calf serum and 10 
μg/ml each of penicillin and streptomycin in a humidified 5% CO2 atmosphere. 
Differentiation of P19 cells down the ectodermal lineage into neuronal cells was 
performed by inducing cell aggregate formation to form embryoid bodies on 
non-adhesive bacterial-grade Petri dishes in the presence of 1 μM of all-trans-
retinoic acid (RA; SigmaAldrich Ltd) at a density of 1 × 10
5
/mL in DMEM 
containing 5% FCS. After 2 days of RA treatment, embryoid bodies were 
dissociated with 0.25% trypsin, 0.53 mM EDTA (Life Technologies Ltd), and 
re-plated in poly-D-lysine-coated (0.1 mg/mL) tissue culture dishes and allowed 
to differentiate for a further 2-8 days in the presence of 10 μM cytosine 
arabinoside to enrich for non-dividing neuronal cells. 
 
2.2.9. Maintenance and differentiation of F9 cells 
 
F9 embryonal carcinoma cells were cultured in DMEM supplemented with 10% 
FCS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 2mM L-glutamine, 
in a humidified 5% CO2 atmosphere on gelatin (0.1%) coated flasks. 
Differentiation of F9 cells into parietal endoderm cells was performed by 
inducing cell embryoid body formation in non-adhesive bacterial-grade Petri 
dishes in the presence of 50 nM RA at a density of 1 × 10
5
/mL in DMEM/F12 
containing 5% FCS. After 5-6 days of RA treatment, embryoid bodies were 
dissociated with 0.25% trypsin, 0.53mM EDTA and re-plated in poly-D-lysine-
coated (0.1 mg/mL) tissue culture dishes and allowed to differentiate for a 
further 2-6 days with 10 μM cytosine arabinoside in the culture medium to 
enrich for non-dividing endodermal cells. 
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2.2.10. Maintenance and differentiation of murine ESCs  
 
Murine CCE embryonic stem cells (ESCs) were maintained in an 
undifferentiated state in DMEM medium (Sigma-Aldrich) supplemented with 
leukemia inhibitory factor (LIF, 103U/mL; Chemicon, Millipore (U.K.) 
Limited, Watford, Herts, UK), 1% L-glutamine, 20% batch tested FBS 
(Summit), 1% penicillin/streptomycin (Sigma-Aldrich) and 1.5x10
4
 M 
monothioglycerol (MTG, Sigma-Aldrich). Cells were cultured in 6 well plates 
coated with 0.1% gelatin in PBS (Sigma-Aldrich). Once 80% confluent, cell 
cultures were trypsynised with 0.25% Trypsin-EDTA (Sigma-Aldrich) and split 
1:2 or 1:3.  
 
Prior to differentiation to embryoid bodies (EBs), cells were passaged and 
cultured in IMDM medium (Life Technologies Ltd) supplemented with the 
same substances as with the DMEM media. 
 
In order to initiate EB formation, cells were trypsinised and re-seeded into non-
adherent, uncoated 60 mm Falcon dishes (Thermo Fisher Scientific) at 
0.375x10
6 
cells/dish in serum-free media (SFD) in the absence of LIF but 
instead containing the following supplements: N2 (Life Technologies), F12 
(Life Technologies), B27 (Life Technologies), IMDM, 1% L-glutamine, 1% 
penicillin/streptomycin, and 10% BSA/PBS (Sigma-Aldrich). Prior to adding 
media to the cells, SFD was further supplemented with 500 mg/mL L-ascorbic 






2.2.11. Vector copy number estimation analysis 
 
To confirm whether reduced eGFP expression over time was due to either loss 
of vector-positive cells from the culture or LV silencing, quantitative PCR 
(qPCR) was performed on total genomic DNA to determine average vector 
copy number (VCN) per cell at each time point of the period of culture after 
transduction. A cell clone harbouring a single A2UCOE-eGFP LV copy was 
isolated by limiting dilution of bulk transduced P19 and F9 cells and used as a 
reference in the VCN qPCR determination. 
 
2.2.12. Immunofluorescence counting of transduced differentiated P19      
and F9 cells 
 
After P19 and F9 cell differentiation to embryoid bodies, the cells were 
removed from the bacterial culture dishes and transferred into 6-well plates, 
within which were placed laminin coated glass coverslips. Upon completion of 
the period of differentiation, immunofluorescence staining was conducting as 
follows.  
Cells on the laminin coated glass coverslips were washed three times with PBS 
and then fixed with 4% paraformaldehyde in PBS twice for 10 min. The fixed 
cells were then treated with blocking buffer (1 x PBS/0.1% Triton X-100) for 30 
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min. The slides were washed with 5% normal serum in PBS three times. 
Primary antibodies anti--tubulin III antibody (Tuj1) for P19 cells and anti-
mouse Oct3/4 for F9 cells, were prepared in PBS + 1% gelatin at a 1/200 and 
1/500 dilution, respectively. The slides with fixed cells were then incubated 
with appropriate primary antibodies for 1hr in a humidified chamber at room 
temperature in the dark. Cells were then washed three times in PBS, 5 min each 
wash. The secondary antibody AlexaFluor 488 goat anti-mouse was then 
applied for 1 hour at room temperature in a humidified chamber. The cells were 
then again washed three times with PBS. Finally, slides were incubated with 
0.1-1 g/mL Hoechst and DAPI for 1 min and the coverslips sealed on 
microscope slides with nail polish to prevent drying and movement under 
microscope. The samples were stored in dark at +4°C.  
Immunofluorescence counting of the cells was conducted under confocal 
microscopy. Neuronal differentiated P19 cells were detected by secondary 
antibody red fluorescence of -tubulin III antigen and endodermal differentiated 



















Evaluating novel candidate 
UCOEs with a dual, divergently 
transcribed housekeeping 






Evaluating novel candidate UCOEs with a dual, divergently transcribed 
housekeeping gene promoter configuration 
 
3.1 Introduction and background 
 
The proposed mechanism, by which the CBX3-HNRPA2B1 UCOE (A2UCOE) 
brings about a dominant chromatin opening function, is a two-component 
system. First, a large (2.7kb) CpG island in association with an extended 
methylation-free region (5kb) with an inherent open chromatin structure and 
second, chromatin remodeling via dual divergent transcription from the innate 
CBX3 and HNRPA2B1 promoters (Allen and Antoniou 2007). The work 
presented in this chapter aimed to further test this two-component mechanism of 
A2UCOE function by evaluating other dual divergent transcription systems 
based on housekeeping genes as in the case of CBX3 and HNRPA2B1. 
 
In addition, it was previously reported that the placement of the core A2UCOE 
upstream of heterologous promoters would confer stability of expression in an 
orientation specific manner; that is, when the CBX3 end of the A2UCOE was 
placed next to the heterologous ubiquitous SFFV (Zhang, Frost et al. 2010) or 
tissue-specific MRP8 (Brendel, Müller-Kuller et al. 2012) promoter elements. It 
was suggested that the reason for this orientation-bias in A2UCOE function 
when linked to heterologous promoters in certain contexts may be due to the 
relatively weak transcriptional activity of the CBX3 promoter compared to that 
of HNRPA2B1. Thus, divergent transcription from the stronger HNRPA2B1 
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promoter would provide a better barrier against epigenetic (DNA methylation, 
histone modification) mediated silencing. We, therefore, sought to construct 
UCOEs with a dual divergent transcriptional configuration but which may 
function equally in either orientation when linked to heterologous promoters.   
               
The lentiviral vector (LV) constructs tested here were conceived and built by a 
previous member of the Antoniou lab (Thalia Vlachou). A search of the 
literature (She, Rohl et al. 2009) and bioinformatics (UCSC Genome Browser) 
analysis of housekeeping genes was undertaken to identify gene pairs based on 
the criteria of high, uniform expression across a variety of normal human 
tissues. Based on this search the SETD3-CCNK housekeeping gene pair was 
chosen as a good novel UCOE candidate. SETD3 and CCNK constitute a dual 
divergently transcribed pair of genes and which are both relatively uniformly 
expressed across 40 different human tissues and cell types. In order to further 
test the hypothesis that the orientation bias of the A2UCOE when linked to 
heterologous promoters was due to the weak transcriptional activity of CBX3, 
an artificial UCOE was constructed whereby the HNRPA2B1 component of the 
A2UCOE was linked to the single promoter-CpG island of the RPS11 
housekeeping gene in a divergently transcribing configuration. The RPS11 
element was again chosen as this gene is expressed at a uniformly high level 






3.2 LV used in this study 
 
Note: the LV constructs SEW (SFFV-eGFP-WPRE), 1.5A2UCOE-SEW, SET-
CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-SEW described below in 
Figure 1 and used in this study were generated by previous members of the 
Antoniou lab (ThaliaVlachou, Olivia Bales).    
 
3.2.1. SEW (SFFV-eGFP-WPRE) 
 
SEW was derived from pHR’SIN-cPPT-SEW (Demaison, Parsley et al. 2002) 
with the addition of a restriction enzyme multi-cloning polylinker inserted at the 
unique EcoRI site 5’ of the SFFV promoter (Figure 3.1). pHR’SIN-cPPT-SEW 
is a second generation HIV-1 based SIN transfer vector, in which the reporter 
gene eGFP is located downstream of the SFFV promoter (Figure 3.1). A WPRE 
element is also present downstream of eGFP. The plasmid vector backbone 

























Figure 3.1. Illustration of the novel candidate UCOE and control lentiviral 
vectors. A standard self-inactivating (SIN) lentiviral vector backbone containing a 
spleen focus forming virus (SFFV) promoter driving expression of an enhanced green 
fluorescent protein (eGFP) reporter gene with downstream woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE) designated as SEW acted as the 
starting point for the construction of test UCOE vectors. The positive control 1.5kb 
HNRPA2B1-CBX3 UCOE (1.5A2UCOE) was inserted into a polylinker (PL) cloning 
site upstream of the SFFV promoter to give 1.5A2UCOE-SEW. Novel candidate 
UCOEs consisting of dual divergently transcribed promoter regions from the human 
SETD3-CCNK locus and artificially constructed RPS11-HNRPA2B1 were inserted 
into the PL in both orientations to give SET-CCN-SEW/CCN-SET-SEW and B1-


























1.5A2UCOE-SEW was generated by subcloning of the 1.5kb core A2UCOE 
fragment (Williams, Mustoe et al. 2005) within the polylinker at the unique 
BstX1-EcoRI sites upstream of the SFFV promoter of SEW (Figure 1). The 
orientation of the 1.5kb A2UCOE in this vector places the CBX3 end of the 
element next to SFFV and thus HNRPA2B1 transcribing in a divergent direction 
(Figure 3.1). This is the orientation found to confer stability of expression from 
the SFFV promoter following transduction into P19 cells (Zhang, Frost et al. 
2010). 
  
3.2.3. SET-CCN-SEW and CCN-SET-SEW 
 
SET-CCN-SEW and CCN-SET-SEW were derived by subcloning of the 
SETD3-CCNK CpG island / dual divergently transcribed promoter region in the 
PacI site of the polylinker upstream of the SFFV promoter of SEW in both 
orientations (Figure 3.1). 
  
3.2.4. B1-RPS-SEW and RPS-B1-SEW  
 
The single promoter CpG island of RPS11 was linked in a divergent 
transcribing orientation to the HNRPA2B1 promoter derived from the A2UCOE 
with CBX3 deleted. B1-RPS-SEW, RPS-B1-SEW are derived by inserting the 
artificially combined dual promoter, CpG island HNRNPA2B1-RPS11 element 
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into the PacI site of the polylinker of SEW upstream of the SFFV promoter 
(Figure 3.1). 
 
3.3 Restriction enzyme digestion confirmation of LV plasmid preparations  
 
The identity and integrity of large-scale maxi-preparations of the plasmid LV to 
be tested (Figure 3.1) was via restriction enzyme digestion and resolution by 
agarose gel electrophoresis. All constructs gave the expected banding pattern 











Figure 3.2. Confirmation of identity and integrity of novel candidate 
UCOE lentiviral vector plasmid preparations. Maxi-preparations of novel 
candidate UCOE (Figure 3.1) plasmid preparations were digested with 
appropriate restriction enzymes and resolved by agarose gel electrophoresis. 
Lane 1: SET-CCN-SEW digestion with BspEI/BamHI to give 795bp, 2725bp 
and 4520bp diagnostic bands. Lane 2: CCN-SET-SEW digestion with 
BspEI/BamHI to give a 2358bp diagnostic band. Lane 3: B1-RPS-SEW 
digestion with BsiWI/BamHI to give a 963bp diagnostic band. Lane 4: RPS-B1-
SEW digestion with BsiWI/BamHI to give a 2158bp diagnostic band. M: 









3.4 Lentiviral vector titration in HEK293T cells 
 
Cells were collected for analysis by flow cytometry three days after the 
transduction of 2x10
5
 HEK293T cells with serial dilutions of harvests at both 2 
and 3 days post-transfection from each production run for all LVs: SEW 
(SFFV-eGFP-WPRE), 1.5A2UCOE-SEW, SET-CCN-SEW, CCN-SET-SEW, 


















                          
                    Volume (µL) of viral vector stock 
2 µL 0.2 µL 0.02 µL 0.002 µL 
                   




 viral harvest 
SEW 62.21 / 74.32 11.38 / 13.57 1.14 / 1.46 0.41 / 0.52 
1.5A2UCOE-SEW  66.23 / 54.6 8.5 / 7.12 0.82 / 1.01 0.21 / 0.3 
SET-CCN-SEW 78.24 / 64.26 14.86 / 11.36 1.84 / 1.23 0.00 / 0.00 
CCN-SET-SEW 24.68 / 16.78 1.65 / 1.47 0.00 / 0.00 0.00 / 0.00 
B1-RPS-SEW 36.81 / 42.11 8.05 / 9.62 1.21 / 1.32 0.23 / 0.33 
RPS-B1-SEW 8.66 / 4.65 0.64 / 0.55 0.00 / 0.00 0.00 / 0.00 
 
Table 3.1: Titration of lentiviral vector (LV) preparations. A 2x10
5
 aliquot of 
HEK293T cells were transduced with 0.002-2 µL of a given LV stock from the first 
and second harvest of virus from culture supernatant during the time of preparation. 
Analysis of eGFP-positive cells at 3-days post-transduction was by flow cytometry. 










3.5 Calculation of LV titre 
 
Viral titre (Table 3.2) was calculated based on the dilution of each harvest that 
gave a percentage of eGFP-positive cells between 1% and 10%. Pools of cells 
with percentages of eGFP-positive cells higher than 10% are very likely to 
contain multiple integrations of the vector, while very low scores could be false 
positives. 
 
On day one, 2x10
5
 293T cells were seeded in each 6-well. Thus, the percentage 
of eGFP positive cells from flow cytometry analysis reflects the percentage of 
the initial cell population that was successfully transduced and hence the 
number of infectious units added in the specified well. The dilution factor or the 
volume of the lentivirus preparation that was used is known, so the calculation 
























SEW 1.14 x 10
8
 1.46 x 10
8
 
1.5A2UCOE-SEW  8.5 x 10
7
 7.12 x 10
7
 
SET-CCN-SEW 1.11 x 10
8
 1.52 x 10
8
 
CCN-SET-SEW 1.65 x 10
7
 1.47 x 10
7
 
B1-RPS-SEW 8.05 x 10
7
 9.62 x 10
7
 
RPS-B1-SEW 8.66 x 10
6




Table 3.2: Lentiviral vector (LV) titres. Viral titre as infectious units per ml 




 harvest of virus that 
gave a percentage of eGFP-positive HEK293T cells between 1-10% (Table 1). 







3.6 Functional assay of candidate UCOEs in undifferentiated P19 and F9 
cells  
 
P19 and F9 cells were transduced with the generated LVs at a MOI of 5 or 10, 
with the intention to start the experiment within the range of 40-60% eGFP-
positive cells in all pools. The transduced cells and negative control were then 
propagated in culture and assayed as a time course by flow cytometry, to 
determine the percentage of eGFP-positive cells and the mean fluorescence 
intensity (MFI) for each repeat transduction for each vector. Cell cultures were 
analysed every 6 days from day 3 post-transduction (Figure 3.3) and extending 
to 52 days (Figure 3.4). Cell samples were taken at regular intervals for the flow 
cytometry analysis, to monitor the expression levels of the eGFP reporter gene. 
In addition, DNA was extracted from cells at each time point for RT-qPCR in 
order to determine the average vector copy number per cell.  
 
Figure 3.4-A shows the flow cytometry time course results depicting percentage 
of eGFP+ cells. Although similar initial transduction efficiency was obtained 
with all vectors (45–60% eGFP+ cells), expression from the SEW (SFFV-
eGFP-WPRE), rapidly declined from 58 to 2% positive cells within 17 days. In 
contrast, the proportion of eGFP+ cells from the 1.5A2UCOE-SEW vector 
remained completely stable over the 52-day period of culture. Therefore, whilst 
differences in the percentage eGFP-positive cells transduced with 1.5A2UCOE-
SEW was significantly higher when compared with the results obtained for all 
other vectors, the decrease of eGFP expression of the vectors SET-CCN-SEW, 
CCN-SET-SEW, B1-RPS-SEW, RPS-B1-SEW is significantly more gradual 
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and slower when compared with SEW. The expression of eGFP in SEW 
transduced cells had dropped almost 80% after 2 weeks post-transduction. 
Contrastingly, with the exception of 1.5A2UCOE-SEW, the reduction observed 
in eGFP-positive cells was only 5% to 12% for all other vectors carrying test 
UCOEs over the same time period. The values of mean fluorescent intensity 
(MFI) for all vectors paralleled the eGFP expression results (Figure 3.4-B). MFI 
was stable in the 1.5A2UCOE-SEW transduced cells, unstable in the case of 


















Figure 3.3: Flow cytometry plots of untransduced and transduced P19 cells. 
P19 cells were transduced with the test LV (Figure 3.1) at a MOI-3 and cells 
analysed by flow cytometry 3 days later. GFP-negative cells are shown with 
red; GFP-positive cells are shown in green. (A) Negative control-untransduced 
cells. (B) SEW transduced cells. (C) 1.5A2UCOE-SEW transduced cells. (D) 
SET-CCN-SEW transduced cells (E) CCN-SET-SEW transduced cells (F) B1-























We next ascertained whether reduced eGFP expression over time was due to the 
loss of vector-positive cells from the culture. Quantitative RT-Q-PCR was 
performed on genomic DNA to determine average vector copy number (VCN) 
at each time point of the period of culture after transduction. Our data show that 
average VCN per cell remained at a similar level for all vectors at all time 
points (Figure 3.4-C). This shows that loss of eGFP expression in cells 
transduced with the SEW and test novel UCOE constructs (Figure 3.4-A) was 















































































Figure 3.4: Novel candidate UCOEs offer only partial protection against 
silencing in undifferentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW lentiviral vectors (Figure 3.1). 
Cells were analysed by flow cytometry to detect percentage of eGFP reporter 
gene expressing (eGFP+) cells, mean fluorescence intensity (MFI) and by RT-
Q-PCR for average vector copy number (VCN) per cell. Data shows combined 
results from three independent transductions for each vector, plus negative 
control (NEG), over a period of 3 to 52 days post-transduction. (A) timecourse 
of percentage eGFP positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in 
(A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but 































Figure 3.6-A shows the flow cytometry time course results depicting percentage 
of eGFP+ cells in undifferentiated F9 cells. The results show a parallel activity 
as with the P19 cells above. Although similar initial transduction efficiency was 
obtained with all vectors (39–50% eGFP+ cells), expression from the SEW 
(SFFV-eGFP-WPRE) rapidly declined from 51% to 3% positive cells within 17 
days. In contrast, the proportion of eGFP+ cells from the 1.5A2UCOE-SEW 
vector remained completely stable over the 52-day period of culture. Therefore, 
whilst differences in the percentage eGFP positive cells transduced with 
1.5A2UCOE-SEW was significantly higher when compared with the results 
obtained for all other vectors, the decrease of eGFP expression of the vectors 
SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-SEW is 
significantly more gradual and slower when compared with SEW. The 
expression of eGFP in SEW transduced cells had dropped almost 80% after 2 
weeks post-transduction. Contrastingly, with the exception of 1.5A2UCOE-
SEW, the reduction observed in eGFP positive cells was only 5% to 10% for all 
other vectors carrying test UCOEs over the same time period. The values of 
mean fluorescent intensity (MFI) for all vectors paralleled the eGFP expression 
results (Figure 3.4-B). MFI was stable in the 1.5A2UCOE-SEW transduced 























Figure 3.5: Flow cytometry plots of untransduced and transduced F9 
cells. 
F9 cells were transduced with the control and novel candidate LV (Figure 
3.1) at MOI 3 and cells analysed by flow cytometry 3 days later. GFP-
negative cells are shown with red; GFP-positive cells are shown in green. (A) 
Negative control-untransduced cells. (B) SEW transduced cells. (C) 
1.5A2UCOE-SEW transduced cells. (D) SET-CCN-SEW transduced cells. 
(E) CCN-SET-SEW transduced cells. (F) B1-RPS-SEW transduced cells. 





















































































Figure 3.6: Novel candidate UCOEs offer only partial protection against 
silencing in undifferentiated F9 cells. F9 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW LVs (Figure 3.1). Cells were 
analysed by flow cytometry to detect percentage of eGFP reporter gene 
expressing (eGFP+) cells, mean fluorescence intensity (MFI) and by real-time 
Q-PCR for average vector copy number (VCN) per cell. Data shows combined 
results from three independent transductions for each vector, plus negative 
control (NEG), over a period of 3 to 52 days post-transduction. (A) timecourse 
of percentage eGFP positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in 
(A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but 




































3.6.1 Functional assay of candidate UCOEs in undifferentiated P19 and F9 
cells   
 
The novel candidate UCOE vectors were able to confer partial stability of 
expression in undifferentiated P19 (Figure 3.4) and F9 (Figure 3.6) cells. We 
next evaluated the ability of these novel LVs to stabilize expression upon 
differentiation of P19 and F9 cells down the neuroectodermal and endodermal 
lineages, respectively.  
 
Cells transduced with each LV were first induced to form embryoid bodies in 
retinoic acid-containing differentiation medium via culture on non-adhesive 
plastic, which is a necessary pre-requisite state for later neuronal and 
endodermal differentiation. Cells subsequently differentiate into a mix of 
neuroectodermal and parietal endoderm cell types, of which fibroblast-like cells 
were the predominant type at the initial stage of differentiation (2-3 days after 
plating for P19 cells and 5-6 days for F9 cells), but with neurons and endoderm 
cells also present. The cultures were then enriched for non-dividing cells by the 
application of 10 μM cytosine arabinoside, in which neurons and endoderm 
cells appear as the only survivors. The optimum incubation time to form 
embryoid bodies and to differentiate the cells into neuroectodermal and 
endoderm cell types was determined as 2-3 days for P19 cells and 5-6 days for 




Prior to differentiation, the quality of the P19 and F9 cell cultures and starting 
percentage of eGFP+ cells was determined by flow cytometry and shown to be 
acceptable (Figures 3.7 and 3.8). 
 
The expression results from triplicate samples of cells transduced with the 
1.5A2UCOE-SEW, SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW LVs following differentiation is presented in Figures 3.8 and 3.10. Our 
data from the differentiation experiments show that expression from the control 
LV carrying the A2UCOE construct (1.5A2UCOE-SEW) has remained stable 
after the P19 and F9 cells were differentiated down the neuronal and endoderm 
lineages, respectively (Figures 3.8-A and 3.10-A). However, the novel 
candidate UCOE vectors SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW and 
RPS-B1-SEW show a gradual reduction in eGFP expression whilst the silencing 
control SEW vector was rapidly repressed (Figures 3.8-A and 3.10-A).  
 
As in the case of undifferentiated cells (Figures 3.4 and 3.6), MFI values upon 
differentiation of both P19 and F9 cells paralleled the eGFP+ cell expression 
data (Figures 3.8-B and 3.10-B) whilst average vector copy number was 
essentially stable throughout the timecourse of the experiment (Figures 3.8-C 
and 3.10-C). 
 
Thus the LVs tested in these experiments gave similar outcomes in 
undifferentiated and differentiated F9 and P19 cells. However, it is perhaps 
noteworthy that the rate of reduction in eGFP expression with the SEW and 
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novel candidate UCOE LVs is greater upon differentiation (Figures 3.8-A and 




















Figure 3.7: Flow cytometry plots of untransduced and transduced P19 cells 
prior to differentiation down the neuroectodermal lineage. P19 cells were 
transduced with the LVs at MOI 3 and cells analysed by flow cytometry 3 days 
later. GFP-negative cells are shown with red; GFP-positive cells are shown in 
green. (A) Negative control-untransduced cells. (B) SEW transduced cells. (C) 
1.5A2UCOE-SEW transduced cells. (D) SET-CCN-SEW transduced cells (E) 
CCN-SET-SEW transduced cells (F) B1-RPS-SEW transduced cells (G) RPS-



















































































Figure 3.8: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW LVs (Figure 3.1) and at 3-days 
post-transduction induced to undergo differentiation down the neuroectodermal 
lineage. Cells were analysed at various times following differentiation by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, 
mean fluorescence intensity (MFI) and by real-time Q-PCR for average vector 
copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 45 days post-transduction (A) timecourse of percentage eGFP 
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 











































Figure 3.9: Flow cytometry plots of untransduced and transduced F9 cells 
prior to differentiation down the endodermal lineage. F9 cells were 
transduced with novel candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-
RPS-SEW, RPS-B1-SEW and control SEW and 1.5A2UCOE-SEW lentiviral 
vectors (Figure 3.1). Cells were analyzed by flow cytometry 3 days post-
transduction. GFP-negative cells are shown in red; GFP-positive cells are 
shown in green. (A) Negative control-untransduced cells. (B) SEW transduced 
cells. (C) 1.5A2UCOE-SEW transduced cells. (D) SET-CCN-SEW transduced 
cells. (E) CCN-SET-SEW transduced cells. (F) B1-RPS-SEW transduced cells. 
















































































Figure 3.10: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated F9 cells. F9 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW LVs (Figure 3.1). At 3-days post 
transduction cells were induced to undergo differentiation down the endodermal 
lineage. Cells were analysed by flow cytometry at periodic intervals to detect 
percentage of eGFP reporter gene expressing (eGFP+) cells, mean fluorescence 
intensity (MFI) and by real-time Q-PCR for average vector copy number (VCN) 
per cell. Data shows combined results from three independent transductions for 
each vector, plus negative control (NEG), over a period of 3 to 41 days post-
transduction. (A) timecourse of percentage eGFP positive cells; (Mean + SEM, 
n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 
**p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean + SEM, n=4; 






























3.7 Immunofluorescence staining and quantification of transduced 
differentiated P19 and F9 cells 
 
In order to confirm the results obtained by flow cytometry (Figures 3.9 and 
3.10), P19 and F9 cells which had undergone neuroectodermal and endodermal  
differentiation, respectively, were stained for appropriate markers and scored 
under immunofluorescence microscopy. This was undertaken as follows: After 
differentiation of cells to embryoid bodies in uncoated bacterial dishes, cells 
were transferred into 6 well-plates containing protein-coated glass cover slips. 
Upon completion of the period of differentiation, cells were stained for 
neuroectodermal (P19 cells) and endodermal (F9 cells) differentiation markers 
and scored by immunofluorescence microscopy for single eGFP or 
differentiation marker positive cells or double positive eGFP plus differentiation 
marker positive cells. More precisely, P19 and F9 cells were scored for 
immunofluorescence staining following differentiation after plating on 1cm
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laminin-coated glass slides. For detection of neuroectodermal differentiation, 
P19 cells were immunofluorescence stained with anti-β-III tubulin (1:500) as 
primary and rhodamine-antimouse Alexa Fluoro 546 (1:200) as secondary 
antibody. Detection of endodermal differentiation, F9 cells were stained for 
Oct3-4 (1:200) as primary antibody and rabbit anti-mouse Alexa Fluoro 488 
(1:500) as secondary antibody. Figure 3.11 shows representative microscopic 
images of undifferentiated and differentiated P19 and Figure 3.12 similarly for 















































Figure 3.11.  Microscopic images of undifferentiated and differentiated P19 
cells.  
A-B: Light microscopy of undifferentiated and untransduced P19 cells; 40X 
magnification. 
C-D: Undifferentiated and untransduced P19 cells after immunofluorescence 
staining with DAPI (panel C) and anti-β-III tubulin (panel D); 40x and 100x 
magnification respectively. As expected cells are only positive for DAPI (blue) 
staining with neither anti-β-III tubulin (red) nor GFP (green) fluorescence. 
E-F: Embryoid bodies (panel E) formed after 2 days of culture in uncoated 
bacterial dishes; 40x magnification. Panel F, P19 cells following 4 days of 
differentiation down the neuroectodermal lineage after embryoid body transfer 
to normal coated tissue culture plates; 100x magnification. 
G-H: Immunofluorescence staining of neuroectodermal differentiated P19 cells 
transduced with a UCOE-eGFP vector; 100x magnification. Panel G, DAPI 
(blue) and anti-β-III tubulin (red) staining. Panel H, anti-β-III tubulin (red) and 



























































Figure 3.12:  Microscopic images of undifferentiated and differentiated F9 
cells.  
A-B: Light microscopy of undifferentiated and untransduced F9 cells. Panel A, 
20x magnification; panel B, 40x magnification. 
C-D: Undifferentiated and untransduced F9 cells after immunofluorescence 
staining with DAPI (panel C) and anti-Oct3-4 (panel D); 40x magnification. As 
expected cells are only positive for DAPI (blue) staining with neither anti-Oct3-
4 (red) nor GFP (green) fluorescence. 
E-F: Embryoid bodies (panel E) formed after 2 days culture in uncoated 
bacterial dishes; 40x magnification. Panel F, F9 cells following 5 days of 
differentiation down the endodermal lineage after embryoid body transfer to 
normal coated tissue culture plates; 100x magnification. 
G-H: Immunofluorescence staining of endodermal differentiated F9 cells 
transduced with a UCOE-eGFP vector. Panel G, DAPI (blue) and anti-Oct3-4 
(red) staining; 20x magnification. Panel H, anti-Oct3-4 (red) and eGFP (green) 










Quantification of immunofluorescence stained cells was as follows: first, all 
cells stained with these markers on the slides were scored. Then, the eGFP 
positive cells that had been transduced with the UCOE-eGFP LVs were also 
counted in the same slides. Between 70 to 90 for P19, and 250 to 300 for F9 
cells were counted in total on each slide to obtain the average number of 
differentiated cells at in 24 days post-differentiation induction. The results 
(Figures 3.13 and 3.14) show the average number of eGFP plus differentiation 
marker double positive cells and confirm those obtained by flow cytometry. 
Expression from the positive control 1.5A2UCOE-SEW vector remained stable 
over the 24 day experimental period whilst the negative control SEW LV was 
silenced within the first two weeks. All novel candidate UCOE vectors showed 












Figure 3.13: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW LVs (Figure 3.1) and at 3-days 
post-transduction induced to undergo differentiation down the neuroectodermal 
lineage. Cells were analysed at various times following differentiation by 
fluorescence microscope by scoring for eGFP and anti--tubulin III double 
positive cells. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 































Figure 3.14: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated F9 cells. F9 cells were transduced with novel 
candidate UCOE SET-CCN-SEW, CCN-SET-SEW, B1-RPS-SEW, RPS-B1-
SEW and control SEW and 1.5A2UCOE-SEW LVs (Figure 3.1) and at 3-days 
post-transduction induced to undergo differentiation down the endodermal 
lineage. Cells were analysed at various times following differentiation by 
fluorescence microscope by scoring for eGFP and anti-Oct3-4 double positive 
cells. Data shows combined results from three independent transductions for 
each vector, plus negative control (NEG), over a period of 3 to 24 days post-






































3.8 Summary and Conclusions  
 
The primary aim of the experiments conducted in this phase of the project was 
to determine whether the novel candidate UCOEs (Figure 3.1) conform with the 
dual divergent transcription model of A2UCOE function (Antoniou, Harland et 
al. 2003, Williams, Mustoe et al. 2005, Allen and Antoniou 2007) and are able 
to confer stability of expression on a linked heterologous promoter regardless of 
their orientation. Although the A2UCOE can confer stability of expression on a 
linked ubiquitous (Williams, Mustoe et al. 2005, Zhang, Frost et al. 2010) or 
tissue-specific (Talbot, Waddington et al. 2009, Brendel, Müller-Kuller et al. 
2011) promoter it does so in an orientation specific manner with the CBX3 end 
of the element abutting the linked promoter. Our starting hypothesis was that 
this problem could be circumvented if both promoters of the selected gene pairs 
showed similar levels and variance of expression in a variety of tissues. That is, 
the reason why uniformity of expression levels both across tissues but also in 
between the gene pair was taken into consideration. In this regard our results are 
encouraging in that both orientations of the SETD3-CCNK element (SET-CCN-
SEW, CCN-SET-SEW) and the artificial HNRPA2B1-RPS11 combination (B1-
RPS-SEW, RPS-B1-SEW) showed similar abilities to confer stability of 
expression from the SFFV promoter independent of orientation (Figures 3.4 and 
3.8).    
 
Stability levels of expression of the novel candidate UCOE vectors as well as 
the controls was analysed in both undifferentiated and neuroectodermal and 
endodermal differentiated P19 and F9 cells, respectively. Our study has thus 
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extended previous investigations, which only looked at expression of UCOE-
based LV profiles in undifferentiated P19 cells (Yoon, Lee et al. 2009, Zhang, 
Frost et al. 2010). The results provide a comparison of the previously reported 
results of the A2UCOE vectors in P19 cells as well as that of the control 
vectors. It is also clear from our results that neither the SETD3-CCNK nor the 
HNRPA2B1-RPS11 elements were as effective as the 1.5A2UCOE-SEW vector 
at negating silencing of the linked SFFV promoter, with eGFP expression from 
the RPS-B1-SEW LV decreasing most rapidly. The 1.5A2UCOE-SEW gave 
perfectly stable expression over the course of our experiment in not only 
undifferentiated P19 cells as previously reported (Zhang, Frost et al. 2010),  but 
also in F9 cells. Furthermore, 1.5A2UCOE-SEW vector maintained stable 
expression upon neuroectodermal and endodermal differentiation of P19 and F9 
cells, respectively. Overall our results provide more evidence of the capacity of 
the A2UCOE present in the configuration found in 1.5A2UCOE-SEW to 
provide stability and reproducibility of transgene expression when linked to a 
heterologous promoter such as SFFV. 
 
Given that the novel candidate UCOEs tested in this phase of the project did not 
match the efficacy of the original A2UCOE, it was decided to focus future work 
on further dissecting the A2UCOE in an effort to identify sub-regions that are 
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Functional dissection of the CBX3-HNRPA2B1 ubiquitous chromatin opening 
element (A2UCOE) 
 
4.1 Introduction and background 
 
In this part of the study we investigated as to whether sub-regions of the HNRPA2B1-
CBX3 UCOE (A2UCOE) retained UCOE activity. This was prompted by a number of 
reports some of which call into question the need for associated promoter activity for 
UCOE function. The relative positions of the sub-regions of the A2UCOE tested are 











Figure 4.1. Illustration of the relative positions of the A2UCOE region sub-
fragments analysed for UCOE activity. Upper panel: CpG density map and 
methylation-free CpG island. Middle panel: Positions of the two alternative first 
exons of CBX3 (orange arrows) and the first exon of HNRPA2B1 (red arrow). Lower 
panel: positions of A2UCOE sub-region fragments analysed for UCOE activity. 
2.2UCOE: fully functional 2.2kb positive control element used to drive expression 
from HNRPA2B1 promoter. 1.5UCOE: fully functional 1.5kb positive control element 
when linked upstream of the SFFV promoter. 0.7UCOE: “Daedalus” test fragment. 
0.9UCOE: core test fragment predicted to constitute a methylation determining region 
(MDR). 945/527/455UCOE: test fragments spanning the most CpG dense region of 
the A2UCOE. The 0.7UCOE, 0.9UCOE and 945/527/455UCOE candidates would be 
tested for their ability to stabilise expression from the silencing prone SFFV promoter 








The first was the publication by Bandarayake and colleagues, which claimed that a 
700bp fragment from the 3’ end of intron I of CBX3 (Figure 4.2, 0.7UCOE), and thus 
devoid of promoter activity, was able to confer stability of expression on a linked 
CMV-GFP reporter construct from within an LV context in CHO cells 
(Bandaranayake, Correnti et al. 2011). If true these data would call into question the 
requirement for associated promoter activity for UCOE function. However, close 
scrutiny of the data presented clearly shows that although the percentage of GFP 
positive cells remains stable over time there is nevertheless a marked (55%) reduction 
in mean fluorescence intensity (MFI) suggesting transgene silencing at 4 weeks post-
transduction (Figure 4.2B). The apparent discrepancy between stability in percentage 
of GFP-positive cells and instability in MFI appears to be due to high (8-10) average 
vector copy number as in principle only one of the integrated LVs need remain 
functional for a given cell to score positive in GFP expression. Based on these 
observations we wished to repeat these experiments but at a low average vector copy 
number per cell to accurately assess the stabilising capability of the promoter-less 
CBX3 first intron derived 0.7UCOE element. We thus linked the same UCOE0.7, 
designated by these authors as “Daedalus”, upstream of the SFFV promoter in 
forward and reverse orientations within the SEW LV (Figure 3.1) to generate the 
constructs Daedalus-F (Forward orientation 0.7kb UCOE-SFFV-eGFP) and 
Daedalus-R (Reverse orientation 0.7kb UCOE-SFFV-eGFP) (Figure 4.3). 
 




Figure 4.2. Lentiviral vectors containing either a CMV-GFP cassette alone or with 5’ 
linked UCOE0.7 from the first intron of CBX3 were used to transduce CHO cells and 
expression looked at over time by flow cytometry. (A) Results from the CMV-GFP 
construct show instability in both percentage of GFP-positive cells (upper panel) and 
MFI (lower table). (B) Results from UCOE0.7-CMV-GFP show stability in 
percentage GFP-positive cells (upper panel) but instability in MFI (lower table). 
Figure adapted from Bandarayake et al., 2011.         
 
The second report was that of Thomson and colleagues (Thomson, Skene et al. 2010). 
This study shows data that suggest that a transgene consisting of a CpG-rich DNA 
fragment lacking a promoter is sufficient to establish a methylation-free region with 
associated active histone modification marks in the absence of RNA polymerase II. 
We, therefore, wished to analyse the most CpG dinucleotide-dense sub-regions of the 
A2UCOE, especially those lacking either the HNRPA2B1 or CBX3 promoters, for 
UCOE function. To this end, the region immediately downstream of the two 
alternative first exons of CBX3 meet these criteria and were thus chosen for further 
functional analysis (Figure 4.1, 945UCOE, 527UCOE, 455UCOE). This 945bp region 
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was divided into two sub-fragments of 455bp and 527bp and all three linked 
individually upstream of the SFFV promoter within the SEW vector (Figure 4.3). 
 
Lastly, a study by Lienert and colleagues shows that sub-fragments of CpG islands 
associated with the promoters of developmentally regulated genes that retain their 
ability to maintain appropriate DNA methylation status in a transgene context 
(Lienert, Wirbelauer et al. 2011). Some of the CpG island sub-fragments tested lacked 
their cognate promoter region. Due to this property, these CpG island sub-regions 
were designated as methylation-determining regions (MDRs). In order to ascertain if 
a similar MDR was present in the housekeeping gene region of the A2UCOE, a 
bioinformatics investigation was conducted to locate a region with specific 
transcription factor binding sites (Sp1, CTCF, USF) that constitute such an element. 
This resulted in a core region of the A2UCOE extending from the first exons of CBX3 
and HNRPA2B1 and thus including both promoter regions being a possible MDR 
(data not shown). In order to test this hypothesis two constructs were built where a 
0.9kb core A2UCOE region encompassing the hypothetical MDR (Figure 4.1) was 
linked upstream of the SFFV promoter within the SEW LV to test its ability to confer 
stability of expression on the latter (Figure 4.3; 0.9UCOE-F and 0.9UCOE-R).  
 
These vectors were functionally analysed for UCOE activity by transducing murine 
embryonal carcinoma P19 and F9 cells, our proven system for evaluating stability of 
viral vector expression (Chapter 3; Zhang et al., 2007 and 2010). The stability, 
potency, and reproducibility of expression of the eGFP transgene were then analysed 
in differentiated and undifferentiated P19 and F9 cells.  
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4.2. Lentiviral vectors used in this study 
 
Note: the LV constructs Daedalus-F, Daedalus-R, 0.9UCOE-F, and 0.9UCOE-R LVs 
were constructed by Kristian Skipper. The bioinformatics analysis leading to the 
location of a putative MDR element within the A2UCOE, and subsequently 
incorporated into the 0.9UCOE-F and 0.9UCOE-R, was also conducted by Kristian 
Skipper. The 945UCOE, 527UCOE, 455UCOE vectors were constructed by our 
collaborators Fang Zhang and Adrian Thrasher at the Institute of Child Health (UCL, 

















Figure 4.3. Illustration of the novel candidate UCOE and control lentiviral 
vectors. A standard self-inactivating (SIN) lentiviral vector backbone containing a 
spleen focus forming virus (SFFV) promoter driving expression of an enhanced green 
fluorescent protein (eGFP) reporter gene with downstream woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE) designated as SEW acted as the 
starting point for the construction of test UCOE vectors. The positive control 1.5kb 
HNRPA2B1-CBX3 UCOE (1.5A2UCOE) was inserted into a polylinker (PL) cloning 
site upstream of the SFFV promoter to give 1.5A2UCOE-SEW. The second positive 
control 2.2kb HNRPA2B1-CBX3 UCOE (2.2A2UCOE) is linked directly to the GFP 
reporter gene driving expression off the HNRPA2B1 promoter to give the construct 
designated 2.2A2UCOE. Novel candidate UCOEs: 0.7UCOE 0.7kb Daedalus-F 
(forward) and Daedalus-R (reverse) constructs; 0.9kb putative methylation 
determining region (MDR) test constructs 0.9UCOE-F (forward), 0.9UCOE-R 
(reverse) orientations; CpG rich region candidate UCOE sub-fragments of 455bp 
455(UCOE), 527bp 527UCOE and 945bp (945UCOE). Novel candidate UCOEs were 





4.2.1 Daedalus-F and Daedalus-R 
 
Daedalus-F (0.7UCOE-SFFV-eGFP) and Daedalus-R (reverse orientation; 0.7UCOE-
R-SFFV-eGFP) constructs were derived from the CBX3 first intron (Figure 4.1, lower 
panel) linked in both orientations upstream of the SFFV promoter (Figure 4.3). This 
0.7kb candidate UCOE is as previously described (Bandaranayake, Correnti et al. 
2011).  
 
4.2.2 0.9UCOE-F and 0.9UCOE-R 
 
The 0.9kb central core A2UCOE region (Figure 4.1, lower panel) constituting a 
hypothetical MDR (methylation determining region; (Lienert, Wirbelauer et al. 2011))  
linked upstream of the SFFV promoter in forward (F) and reverse (R) orientations 
within SEW (Figure 4.3). 
 
4.2.3 455UCOE, 527UCOE, 945UCOE  
 
Fragments encompassing the most CpG dense regions within intron I of CBX3 of 
455bp, 527bp and 945bp in length (Figure 4.1, lower panel) linked upstream of the 
SFFV promoter in their native orientation within SEW (Figure 4.3). These were 
obtained from our collaborators at the Institute of Child Health (UCL, UK). They are 
based on a reported finding that promoter-less CpG rich regions can establish an open 
chromatin structure (Thomson, Skene et al. 2010). Thus, CpG rich regions from the 
CBX3 side of the A2UCOE and devoid of promoter activity were tested to see if they 
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could retain chromatin-opening capability and confer stability of expression from a 
linked SFFV promoter.  
 
4.3 Lentiviral vector titration in HEK293T cells 
 
Cells were collected for analysis by flow cytometry three days after the transduction 
of 2x10
5
 HEK293T cells with serial dilutions of harvests at both 2 and 3 days post-
transfection from each production run for all LVs: SEW (SFFV-eGFP-WPRE), 
1.5A2UCOE-SEW, 2.2A2UCOE, Daedalus-F/R, 0.9UCOE-F/R, 455UCOE, 

















                          
                    Volume (µL) of viral vector stock 
2 µL 0.2 µL 0.02 µL 0.002 µL 
                   




 viral harvest 
SEW     84.01 / 71.22      15.28 / 11.52    3.11 / 1.86 0.6 / 0.42 
1.5A2UCOE-
SEW  
      74.43 / 51.3       11.3 / 9.14 1.8 / 1.44 0.7 / 0.4 
2.2A2UCOE       83.4 / 74.66      18.26 / 13.62      2.24 / 1.83 0.5 / 0.3 
DAEDALUS-F      64.98/62.18 9.5 / 8.4        1.2 / 1.01 0.2 / 0.1 
DAEDALUS-R    76.21 / 62.14        7.25 / 6.32      1.44 / 1.11 0.22 / 0.11 
0.9UCOE-F 86.6 / 75.2 8.66 / 6.55       2.32 / 1.87 0.00 / 0.00 
0.9UCOE-R 63.1 / 55.4 5.26 / 3.15       0.82 / 0.57 0.00 / 0.00 
455UCOE 76.1 / 72.2        13.76 / 11.45        2.86 / 1.88 0.4 / 0.2 
527UCOE       83.66 / 72.22       18.46 / 13.15         3.44 / 
2.17 
0.6 / 0.4 




Table 4.1. Titration of lentiviral vector (LV) preparations. A 2x10
5
 aliquot of 
HEK293T cells were transduced with 0.002-2 µl of a given LV stock from the first 
and second harvest of virus from culture supernatant during the time of preparation. 
Analysis of eGFP positive cells at 3-days post-transduction was by flow cytometry. 


























4.3.1 Calculation of LV titre 
 
Viral titre (Table 4.2) was calculated based on the dilution of each harvest that gave a 
percentage of eGFP-positive cells between 1% and 10%. Pools of cells with 
percentages of eGFP-positive cells higher than 10% are very likely to contain 
multiple integrations of the vector, while very low scores could be false positives. 
 
On day one, 2x10
5
 293T cells were seeded in each 6-well. Thus, the percentage of 
eGFP-positive cells from flow cytometry analysis, reflects the percentage of the initial 
cell population that was successfully transduced and hence the number of infectious 
units added in the specified well. The dilution factor or the volume of the lentivirus 
preparation that was used is known, so the calculation of the number of infectious 























1.5A2UCOE-SEW 1.46 x 10
8
 1.14 x 10
8
 
2.2A2UCOE 2.17 x 10
8
 1.84 x 10
8
 
DAEDALUS-F 1.51 x 10
8
 1.05 x 10
8
 
DAEDALUS-R 1.82 x 10
8
 1.12 x 10
8
 
0.9UCOE-F 1.26 x 10
8
 0.63 x 10
8
 
0.9UCOE-R 1.73 x 10
8
 1.03 x 10
8
 
455UCOE 1.51 x 10
8
 0.91 x 10
8
 
527UCOE 1.94 x 10
8
 1.31 x 10
8
 
945UCOE 1.75 x 10
8





Table 4.2. Lentiviral vector (LV) titres. Viral titre as infectious units per ml (iu/mL) 




 harvest of virus that gave a 
percentage of eGFP-positive HEK293T cells between 1% and 10% (Table 4.1). LV 



























4.4 Functional analysis Daedalus-F and Daedalus-R candidate UCOE LVs 
in undifferentiated P19 and F9 cells  
 
P19 and F9 cells were transduced with the generated LVs at a MOI of 3 or 6, with the 
intention to start the experiment within the range of 40-60% eGFP-positive cells in all 
pools. The transduced cells and negative control were then propagated in culture and 
assayed as a time course by flow cytometry, to determine the percentage of eGFP-
positive cells and the mean fluorescence intensity (MFI) for each repeat transduction 
for each vector. Cell cultures were analysed every 7 days from day 3 post-
transduction and extending to 45 days (Figure 4.4 and 4.5). Cell samples were taken 
at regular intervals for the flow cytometry analysis, to monitor the expression levels 
of the eGFP reporter gene. In addition, DNA was extracted from cells at each time 
point for RT-qPCR in order to determine the average vector copy number per cell.  
 
Figure 4.4A shows the flow cytometry time course results depicting percentage of 
eGFP+ cells. Although similar initial transduction efficiency was obtained with all 
vectors (45%-60% eGFP+ cells), expression from the SEW (SFFV-eGFP-WPRE), 
rapidly declined from 46 to 3% positive cells within 17 days. In contrast, the 
proportion of eGFP+ cells from the 1.5A2UCOE-SEW vector remained completely 
stable over the 45-day period of culture. Therefore, whilst differences in the 
percentage of eGFP-positive cells transduced with 1.5A2UCOE-SEW was 
significantly higher when compared with the results obtained for all other vectors, the 
decrease of eGFP expression of both the Daedalus-F and Daedalus-R vectors is 
parallel to that seen with SEW. The expression of eGFP in SEW transduced cells had 
dropped almost 80% at 2 weeks post-transduction. Similarly, with the exception of 
1.5A2UCOE-SEW, the reduction observed in eGFP-positive cells was 40% to 50% 
122 
 
for all other vectors carrying the test Daedalus-F and Daedalus-R over the same time 
period. The values of mean fluorescent intensity (MFI) for all vectors paralleled the 
expression results on a percentage eGFP-positive cell basis (Figure 4.4B). MFI was 
stable in the 1.5A2UCOE-SEW transduced cells and unstable in the case of SEW and 





























































































Figure 4.4. Novel candidate Daedalus-F and Daedalus-R UCOEs offer only 
partial protection against silencing in undifferentiated P19 cells. P19 cells were 
transduced with novel candidate UCOE Daedalus-F, Daedalus-R and control SEW 
and 1.5A2UCOE-SEW lentiviral vectors (Figure 4.3). Cells were analysed by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, mean 
fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy number 
(VCN) per cell. Data shows combined results from three independent transductions 
for each vector, plus negative control (NEG), over a period of 3 to 45 days post-
transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; 
**p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in 



































Figure 4.5A shows the flow cytometry time course results depicting percentage of 
eGFP+ cells in transduced undifferentiated F9 cells. The results parallel those we 
observed in P19 cells (Figure 4.4A). Although a similar initial transduction efficiency 
was obtained with all vectors (39%-50% eGFP+ cells), expression from the SEW 
(SFFV-eGFP-WPRE), rapidly declined from 47% to 7% eGFP+ cells within 17 days. 
In contrast, the proportion of eGFP+ cells (~45%) from the 1.5A2UCOE-SEW vector 
remained completely stable over the 38-day period of culture. The UCOE candidate 
Daedalus-F and Daedalus-R constructs showed a very similar rate of decline in 
expression to that seen with SEW. The expression of eGFP in SEW transduced cells 
had dropped almost 80% after 2 weeks post-transduction. Similarly, with the 
exception of 1.5A2UCOE-SEW, the reduction observed in eGFP+ cells were 40% to 
50% for the test UCOE Daedalus-F and Daedalus-R LVs over the same time period. 
The values of mean fluorescent intensity (MFI) for all vectors paralleled the eGFP 
expression results (Figure 4.5B). MFI was stable in the 1.5A2UCOE-SEW transduced 

















































































Figure 4.5. Novel candidate UCOE Daedalus-F and Daedalus-R offer only 
partial protection against silencing in undifferentiated F9 cells. F9 cells 
were transduced with novel candidate UCOE Daedalus-F and Daedalus-R and 
control SEW and 1.5A2UCOE-SEW LVs (Figure 4.3). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) 
cells, mean fluorescence intensity (MFI) and by real-time Q-PCR for average 
vector copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 38 days post-transduction. (A) time course of percentage eGFP 
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 































Average vector copy number per cell in both P19 (Figure 4.4C) and F9 (Figure 4.5C) 
cell transduction experiments remained stable throughout the period of culture 
demonstrating that reduction in eGFP-positive cells in the SEW and Daedalus-F and 
Daedalus-R constructs was not due to vector loss but to silencing of integration 
events.     
 
4.5 Functional assay of candidate UCOEs Daedalus-F and Daedalus-R in 
differentiated P19 and F9 cells  
 
The novel candidate UCOE Daedalus-F and Daedalus-R vectors were not able to 
confer stability of expression in undifferentiated P19 (Figure 4.4) and F9 (Figure 4.5) 
cells. We next evaluated the ability of these novel LVs to stabilize expression upon 
differentiation of P19 and F9 cells down the neuroectodermal and endodermal 
lineages, respectively.   
 
Cells transduced with each LV were first induced to form embryoid bodies in retinoic 
acid-containing differentiation medium via culture on non-adhesive plastic, which is a 
necessary pre-requisite state for latter neuronal and endodermal differentiation. Cells 
subsequently differentiate into a mix of neuroectodermal and parietal endoderm cell 
types, of which fibroblast-like cells were the predominant type at the initial stage of 
differentiation (2-3 days after plating for P19 cells and 5-6 days for F9 cells), but with 
neurons and endoderm cells also present. The cultures were then enriched for non-
dividing cells by the application of 10 μM cytosine arabinoside, in which neurons and 
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endoderm cells appear as the only survivors. The optimum incubation time to form 
embryoid bodies and to differentiate the cells into neuroectodermal and endoderm cell 
types was determined as 2-3 days for P19 cells and 5-6 days for F9 cells.  
 
The expression results obtained by flow cytometry of the total cell population from 
triplicate samples of cells transduced with the SEW, 1.5A2UCOE-SEW, Daedalus-F 
and Daedalus-R LVs following differentiation is presented in Figures 4.6 and 4.7. Our 
data from the differentiation experiments show that the positive control LV carrying 
the 1.5kb A2UCOE construct (1.5A2UCOE-SEW) has remained stable after the P19 
and F9 cells were differentiated down the neuronal and endoderm lineages, 
respectively (Figures 4.6A and 4.7A). However, the novel candidate UCOE vectors 
Daedalus-F and Daedalus-R show a rapid reduction in eGFP expression whilst eGFP 
expression in the silencing control SEW vector was also rapidly repressed (Figures 
4.6A and 4.7A).  
 
As in the case of undifferentiated cells (Figures 4.4B and 4.5B), MFI values upon 
differentiation of both P19 and F9 cells paralleled the eGFP+ cell expression data 
(Figures 4.6B and 4.7B) whilst average vector copy number was essentially stable 
throughout the timecourse of the experiment (Figures 4.6C and 4.7C). 
 
Thus, the LVs tested in these experiments gave similar outcomes in undifferentiated 
and differentiated F9 and P19 cells. However, it is perhaps noteworthy that the rate of 
reduction in eGFP expression with the SEW and novel candidate UCOE LVs is 
greater upon differentiation (Figures 4.6A and 4.7A) than in undifferentiated (Figures 




As the Daedalus-F and Daedalus-R vectors did not provide stable expression in 
differentiated P19 or F9 cells, it was deemed unnecessary to conduct 






















































































Figure 4.6. Novel candidate UCOEs Daedalus-F and Daedalus-R offer only 
partial protection against silencing in differentiated P19 cells. P19 cells were 
transduced with novel candidate UCOE Daedalus-F and Daedalus-R, control SEW 
and 1.5A2UCOE-SEW LVs (Figure 4.3). Cells were analysed by flow cytometry to 
detect percentage of eGFP reporter gene expressing (eGFP+) cells, mean fluorescence 
intensity (MFI) and by real-time Q-PCR for average vector copy number (VCN) per 
cell. Data shows combined results from three independent transductions for each 
vector, plus negative control (NEG), over a period of 3 to 38 days post-transduction. 
(A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; **p<0.01). 
(B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) 


































































































Figure 4.7. Novel candidate UCOEs Daedalus-F and Daedalus-R offer only 
partial protection against silencing in differentiated F9 cells. F9 cells were 
transduced with novel candidate UCOE Daedalus-F, Daedalus-R, control SEW and 
1.5A2UCOE-SEW LVs (Figure 4.3). Cells were analysed by flow cytometry to detect 
percentage of eGFP reporter gene expressing (eGFP+) cells, mean fluorescence 
intensity (MFI) and by real-time Q-PCR for average vector copy number (VCN) per 
cell. Data shows combined results from three independent transductions for each 
vector, plus negative control (NEG), over a period of 3 to 38 days post-transduction. 
(A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; **p<0.01). 
(B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) 































Because the both Daedalus constructs have not shown any stability, we decided not to 
make immunofluorescence staining counting of the differentiated cells. 
 
4.6. Functional analysis of candidate 0.9UCOE-F and 0.9UCOE-R in 
undifferentiated P19 and F9 cells  
 
P19 and F9 cells were transduced with the candidate 0.9UCOE-F and 0.9UCOE-R 
LVs (Figure 4.3) harbouring a putative MDR at MOI of 3 or 6, with the intention to 
start the experiment within the range of 40-60% eGFP-positive cells in all pools. The 
transduced cells and negative control were then propagated in culture and assayed as a 
time course by flow cytometry, to determine the percentage of eGFP positive cells 
and the mean fluorescence intensity (MFI) for each repeat transduction for each 
vector. Cell cultures were analysed every 7 days from day 3 post-transduction and 
extending to 31 days (Figure 4.8 and 4.9). In addition, DNA was extracted from cells 
at each time point for RT-qPCR in order to determine the average vector copy number 
per cell.  
 
Figure 4.8A shows the flow cytometry time course results depicting percentage of 
eGFP+ cells. Although similar initial transduction efficiency was obtained with all 
vectors (45–60% eGFP+ cells), as we see reproducibly expression from the SEW 
(SFFV-eGFP-WPRE), rapidly declined from 45% to 2% positive cells within 17 days. 
In contrast, the proportion of eGFP+ cells from the 1.5A2UCOE-SEW and 
2.2A2UCOE positive control vectors remained completely stable over the 31-day 
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period of culture.  Expression from the 0.9UCOE-F and 0.9UCOE-R LVs where the 
0.9kb core A2UCOE is linked to the SFFV promoter is also unstable but the rate of 
decrease in eGFP+ cells is markedly slower than that from SEW. The expression of 
eGFP in SEW transduced cells had dropped almost 80% after 2 weeks post-
transduction. Contrastingly, the reduction we observed in eGFP+ cells for the 
0.9UCOE-F and 0.9UCOE-R LVs was only 20% to 30% over the same time period. 
The values of mean fluorescent intensity (MFI) for all vectors paralleled the eGFP 
expression results (Figure 4.8B). MFI was stable in the 1.5A2UCOE-SEW transduced 
cells, unstable in the case of SEW and in the novel test 0.9UCOE-F and 0.9UCOE-R 
LV constructs. As consistently observed the average vector copy number per cell 
remained stable in all cases over the entire period of the experiment (Figure 4.8C), 
thus confirming that reduced levels of eGFP expression with the SEW, 0.9UCOE-F 
















































































Figure 4.8. Novel candidate UCOEs 0.9UCOE-F and 0.9UCOE-R offer partial 
protection against silencing in undifferentiated P19 cells. P19 cells were 
transduced with the novel candidate UCOE constructs 0.9UCOE-F and 0.9UCOE-R  
and control SEW, 1.5A2UCOE-SEW and 2.2kbA2UCOE LVs (Figure 4.3). Cells 
were analysed by flow cytometry to detect percentage of eGFP reporter gene 
expressing (eGFP+) cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for 
average vector copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a period 
of 3 to 31 days post-transduction. (A) timecourse of percentage eGFP-positive cells; 
(Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 


































Figure 4.9A shows the flow cytometry time course results depicting percentage of 
eGFP+ cells in undifferentiated F9 cells transduced with the same 0.9UCOE-F and 
0.9UCOE-R LVs. The results show a parallel activity to that we observed in P19 cells 
(Figure 4.8A). Although similar initial transduction efficiency was obtained with all 
vectors (39–50% eGFP+ cells), expression from SEW (SFFV-eGFP-WPRE) rapidly 
declined from 44% to 3% positive cells within 17 days. As in the case with P19 cells 
(Figure 4.8A), the proportion of eGFP+ cells from the 1.5A2UCOE-SEW and 
2.2A2UCOE vectors remained completely stable over the 31-day period of culture. 
Again, expression from the candidate 0.9UCOE-F and 0.9UCOE-R LVs also declined 
over time but at significantly slower rates compared with SEW. The expression of 
eGFP in SEW transduced cells had dropped almost 80% after 2 weeks post-
transduction. Contrastingly, the reduction observed in eGFP+ cells was only 5-10% 
for the 0.9UCOE-F and 0.9UCOE-R LVs over the same time period. The values of 
mean fluorescent intensity (MFI) for all vectors paralleled the eGFP expression 
results (Figure 4.9B). MFI was stable in the 1.5A2UCOE-SEW and 2.2A2UCOE 
transduced cells, unstable in the case of SEW and partially stable in the novel test 
UCOE constructs. Analysis of average vector copy number per cell revealed that this 










































































Figure 4.9. Novel candidate UCOEs 0.9UCOE-F and 0.9UCOE-R offer partial 
protection against silencing in undifferentiated F9 cells. F9 cells were transduced 
with novel candidate UCOE 0.9UCOE-F and 0.9UCOE-R, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were analysed by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, mean 
fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy number 
(VCN) per cell. Data shows combined results from three independent transductions 
for each vector, plus negative control (NEG), over a period of 3 to 31 days post-
transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; 
**p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in 
































4.7 Functional assay of candidate 0.9UCOE-F and 0.9UCOE-R UCOEs in 
differentiated P19 and F9 cells  
 
The novel candidate UCOE 0.9UCOE-F and 0.9UCOE-R vectors were able to confer 
partial stability of expression in undifferentiated P19 (Figure 4.8) and F9 (Figure 4.9) 
cells. We next evaluated the ability of these novel LVs to stabilize expression upon 
differentiation of P19 and F9 cells down the neuroectodermal and endodermal 
lineages, respectively.  
 
P19 and F9 cells transduced with each LV were first induced to form embryoid bodies 
in retinoic acid-containing differentiation medium and subsequent neuroectodermal 
and parietal endoderm cell differentiation, respectively as before.  
 
The expression results from triplicate samples of cells transduced with the SEW, 
1.5A2UCOE-SEW, 2.2A2UCOE, 0.9UCOE-F and 0.9UCOE-R LVs following 
differentiation is presented in Figures 4.10 and 4.11. Our data show that the control 
LVs carrying the positive UCOE constructs (1.5A2UCOE-SEW and 2.2A2UCOE) 
retained stable expression after P19 (Figure 4.10A) and F9 (Figure 4.11A) cell 
differentiation. However, the novel candidate UCOE vectors 0.9UCOE-F and 
0.9UCOE-R show a gradual reduction in eGFP expression whilst eGFP in the 




As in the case of undifferentiated cells (Figures 4.8 and 4.9), MFI values upon 
differentiation of both P19 and F9 cells paralleled the eGFP+ cell expression data 
(Figures 4.10B and 4.11B) whilst average vector copy number was essentially stable 
throughout the timecourse of the experiment (Figures 4.10C and 4.11C). 
 
Thus the LVs tested in these experiments gave similar outcomes in undifferentiated 
and differentiated F9 and P19 cells. Interestingly, the rate of reduction in eGFP 
expression with the SEW and novel candidate 0.9UCOE-F and 0.9UCOE-R LVs is 
greater upon differentiation (Figures 4.10A and 4.11A) than in undifferentiated cells 

















































































Figure 4.10. Novel candidate 0.9UCOE-F and 0.9UCOE-R UCOEs offer partial 
protection against silencing in differentiated P19 cells. P19 cells were transduced 
with novel candidate UCOE 0.9UCOE-F and 0.9UCOE-R, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were analysed by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, mean 
fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy number 
(VCN) per cell. Data shows combined results from three independent transductions 
for each vector, plus negative control (NEG), over a period of 3 to 31 days post-
transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; 
**p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in 




























































































Figure 4.11. Novel candidate 0.9UCOE-F and 0.9UCOE-R UCOEs offer partial 
protection against silencing in differentiated F9 cells. F9 cells were transduced 
with novel candidate UCOE 0.9UCOE-F and 0.9UCOE-R, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were analysed by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, mean 
fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy number 
(VCN) per cell. Data shows combined results from three independent transductions 
for each vector, plus negative control (NEG), over a period of 3 to 31 days post-
transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + SEM, n=4; 
**p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; **p<0.01). (C) As in 


























4.8 Evaluation of novel candidate 0.9UCOE-F and 0.9UCOE-R UCOE 
LVs in differentiated P19 and F9 cells by immunofluorescence staining  
 
In order to confirm the results obtained by flow cytometry with differentiated 
P19 and F9 cells transduced with the novel candidate 0.9UCOE-F and 
0.9UCOE-R UCOE LVs (Figures 4.10 and 4.11), P19 and F9 cells which had 
undergone neuroectodermal and endodermal  differentiation, respectively, were 
stained for appropriate markers and scored under immunofluorescence 
microscopy (see section 3.7). The results depicting transduced GFP plus -
tubulin III double-positive differentiated P19 cells are shown in Figure 4.12 and 
GFP plus Oct3-4 double-positive differentiated F9 cells in Figure 4.13. These 
data corroborate the results obtained by flow cytometry (Figures 4.10 and 4.11) 
and show that the 0.9UCOE-F and 0.9UCOE-R candidate UCOEs confer only 
marginal protection against silencing of the linked SFFV promoter over during 











Figure 4.12: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE 0.9UCOE-F and 0.9UCOE-R, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3) and at 3-days post-
transduction induced to undergo differentiation down the neuroectodermal 
lineage. Cells were analysed at various times following differentiation by 
fluorescence microscopy by scoring for GFP and anti--tubulin III double 
positive cells. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 



































Figure 4.13: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated F9 cells. F9 cells were transduced with novel 
candidate 0.9UCOE-F and 0.9UCOE-R and control SEW, 1.5A2UCOE-SEW 
and 2.2A2UCOE LVs (Figure 4.3) and at 3-days post-transduction induced to 
undergo differentiation down the endodermal lineage. Cells were analysed at 
various times following differentiation by fluorescence microscope by scoring 
for GFP and anti-Oct3-4 double positive cells. Data shows combined results 
from three independent transductions for each vector, plus negative control 

































4.9 Functional assay of candidate 455UCOE, 527UCOE and 945UCOE LVs 
in undifferentiated P19 and F9 cells  
 
P19 and F9 cells were transduced with the novel candidate 455UCOE, 527UCOE and 
945UCOE LVs at a MOI of 3 or 6, with the intention to start the experiment within 
the range of 40-60% eGFP+ cells in all pools. The transduced cells and negative 
control were then propagated in culture and assayed as a time course by flow 
cytometry, to determine the percentage of eGFP-positive cells and the mean 
fluorescence intensity (MFI) for each repeat transduction for each vector. Cell 
cultures were analysed every 7 days from day 3 post-transduction and extending to 31 
days (Figure 4.12 and 4.13). In addition, DNA was extracted from cells at each time 
point for RT-qPCR in order to determine the average vector copy number per cell.  
 
Figure 4.12A shows the flow cytometry time course results depicting percentage of 
eGFP+ cells. A similar initial transduction efficiency was obtained with all vectors 
(45–60% eGFP+ cells). As expected expression from SEW (SFFV-eGFP-WPRE), 
rapidly declined from 43% to 2% eGFP+ positive cells within 17 days whilst the 
proportion of eGFP-positive cells from the 1.5A2UCOE-SEW and 2.2A2UCOE 
vectors remained completely stable over the 31-day period of culture. The novel 
candidate 455UCOE, 527UCOE and 945UCOE LVs also resulted in a rapid decrease 
of eGFP expression in parallel to that seen with SEW. The expression of eGFP with 
SEW transduced cells dropped almost 80% after 2 weeks post-transduction. Similarly, 
a 60-70% reduction in eGFP-positive cells occurred with the test 455UCOE, 
527UCOE and 945UCOE LVs over the same time period. The MFI values for all 
vectors matched the eGFP expression results (Figure 4.12B). MFI was stable in the 
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1.5A2UCOE-SEW and 2.2A2UCOE transduced cells and unstable for both the SEW 


























































































Figure 4.14. Novel candidate 455UCOE, 527UCOE and 945UCOE do not confer 
protection against silencing in undifferentiated P19 cells. P19 cells were 
transduced with novel candidate 455UCOE, 527UCOE and 945UCOE constructs as 
well as control SEW, 1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells 
were analysed by flow cytometry to detect percentage of eGFP reporter gene 
expressing (eGFP+) cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for 
average vector copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a period 
of 3 to 31 days post-transduction. (A) timecourse of percentage eGFP-positive cells; 
(Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 





























Figure 4.13A shows the flow cytometry time course results from undifferentiated F9 
cells transduced with the 455UCOE, 527UCOE and 945UCOE LVs. The results are 
very similar to what we observed in undifferentiated P19 cells (Figure 4.12A). 
Following transduction to give a similar initial level of eGFP+ cells in all cases (39–
50% eGFP+ cells), expression of eGFP from SEW (SFFV-eGFP-WPRE) gave the 
usual rapid decline from 47% to 2% positive cells within 17 days (Figure 4.13A). 
Again, as expected, the proportion of eGFP+ cells from the positive control 
1.5A2UCOE-SEW and 2.2A2UCOE vectors remained completely stable over the 38-
day period of culture. Expression from the candidate 455UCOE, 527UCOE and 
945UCOE vectors  as in the case of P19 cells (Figure 4.12A) again resulted in a 
comparable rapid decline in eGFP+ cells to that seen with SEW (Figure 4.13A). As 
we have consistently seen, the expression of eGFP in SEW transduced cells had 
dropped almost 80% after 2 weeks post-transduction. Similarly, we observed a 40-
50% reduction in eGFP-positive cells with the candidate 455UCOE, 527UCOE and 
945UCOE LVs over the same time period. The MFI values for all vectors paralleled 
the eGFP expression results (Figure 4.13B). MFI was stable in the 1.5A2UCOE-SEW 
transduced cells and unstable in the case of SEW and the novel 455UCOE, 527UCOE 
and 945UCOE test constructs. The average vector copy number per cell was 
essentially unchanged in all cases during the course of the experiment confirming that 





































































Figure 4.15. Novel candidate 455UCOE, 527UCOE and 945UCOE LVs do not 
confer protection against silencing in undifferentiated F9 cells. F9 cells were 
transduced with novel candidate 455UCOE, 527UCOE and 945UCOE constructs, and 
control SEW, 1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were 
analysed by flow cytometry to detect percentage of eGFP reporter gene expressing 
(eGFP+) cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for average 
vector copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a period 
of 3 to 31 days post-transduction. (A) timecourse of percentage eGFP-positive cells; 
(Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 






























4.10 Functional analysis of candidate 455UCOE, 527UCOE and 945UCOE 
LVs in differentiated P19 and F9 cells  
 
The novel candidate 455UCOE, 527UCOE and 945UCOE vectors were unable to 
confer stability of expression in undifferentiated P19 (Figure 4.12) and F9 (Figure 
4.13) cells. In order to confirm and extend the data implying a lack of UCOE function 
from these constructs, we next evaluated their efficiency of expression during 
differentiation of P19 and F9 cells down the neuroectodermal and endodermal 
lineages, respectively.  
 
Our standard conditions were used to induce cells transduced with each LV to 
undergo differentiation via an embryoid body stage in the presence of retinoic acid-
containing medium. The expression results from triplicate samples of cells transduced 
with the SEW, 1.5A2UCOE-SEW, 2.2A2UCOE, 455UCOE, 527UCOE and 
945UCOE LVs following differentiation is presented in Figures 4.14 and 4.15. Our 
data show that the positive control LVs (1.5A2UCOE-SEW and 2.2A2UCOE) have 
retained stable expression after the P19 (Figure 4.14A) and F9 (Figure 4.15A) cells 
had undergone differentiation down the neuronal and endoderm lineages, 
respectively. However, the novel candidate 455UCOE, 527UCOE and 945UCOE  
vectors showed a similar rapid reduction in eGFP expression to that of the silencing 
control SEW LV (Figures 4.14A and 4.15A).  
 
As in the case of undifferentiated cells (Figures 4.12B and 4.13B), MFI values upon 
differentiation of both P19 and F9 cells paralleled the eGFP+ cell expression data 
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(Figures 4.14B and 4.15B) whilst average vector copy number was essentially stable 
throughout the timecourse of the experiment (Figures 4.14C and 4.15C). 
 
Thus the LVs tested in these experiments gave similar outcomes in both 
undifferentiated and differentiated F9 and P19 cells. As we have seen previously with 
other candidate UCOEs, the rate of reduction in eGFP expression with the novel 
candidate 455UCOE, 527UCOE and 945UCOE  LVs is greater upon differentiation 



















































































Figure 4.16. Novel candidate 455UCOE, 527UCOE and 945UCOE LVs do not 
offer protection against silencing in differentiated P19 cells. P19 cells were 
transduced with novel candidate 455UCOE, 527UCOE and 945UCOE, and control 
SEW, 1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, 
mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy 
number (VCN) per cell. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 31 
days post-transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + 
SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 






















































































Figure 4.17. Novel candidate 455UCOE, 527UCOE and 945UCOE LVs do not 
offer protection against silencing in differentiated F9 cells. F9 cells were 
transduced with novel candidate 455UCOE, 527UCOE and 945UCOE, and control 
SEW, 1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, 
mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector copy 
number (VCN) per cell. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 31 
days post-transduction. (A) timecourse of percentage eGFP-positive cells; (Mean + 
SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, n=4; 


























4.11 Functional analysis of candidate 455UCOE, 527UCOE and 
945UCOE LVs in differentiated P19 and F9 cells by 
immunofluorescence staining 
 
As before, in order to confirm the results obtained by flow cytometry (Figures 
4.16 and 4.17), P19 and F9 cells which had undergone neuroectodermal and 
endodermal  differentiation, respectively, were stained for appropriate markers 
and scored under immunofluorescence microscopy. The results of transduced 
GFP plus -tubulin III double-positive P19 cells (Figure 4.18) and GFP plus 
Oct3-4 double-positive F9 cells (Figure 4.19) are in complete agreement with 
the flow cytometry data (Figures 4.16 and 4.17) and show that the candidate 
455UCOE, 527UCOE and 945UCOE constructs fail to protect the linked SFFV 











Figure 4.18: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated P19 cells. P19 cells were transduced with novel 
candidate 455UCOE, 527UCOE and 945UCOE, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3) and at 3-days post-
transduction induced to undergo differentiation down the neuroectodermal 
lineage. Cells were analysed at various times following differentiation by 
immunofluorescence microscopy scoring for GFP plus -tubulin III double-
positive cells. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 


































Figure 4.19: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated F9 cells. F9 cells were transduced with novel 
candidate 455UCOE, 527UCOE and 945UCOE, and control SEW, 
1.5A2UCOE-SEW and 2.2A2UCOE LVs (Figure 4.3) and at 3-days post-
transduction induced to undergo differentiation down the endodermal lineage. 
Cells were analysed at various times following differentiation by 
immunofluorescence microscopy scoring for GFP plus Oct3-4 double-positive 
cells. Data shows combined results from three independent transductions for 
each vector, plus negative control (NEG), over a period of 3 to 24 days post-



































4.12 Summary and Conclusions  
 
The primary aim of the experiments conducted in this phase of the project was to 
determine whether sub-regions of the A2UCOE derived from the human HNRPA2B1-
CBX3 locus (Figure 4.1) retain UCOE function. This work was inspired by previous 
reports, which claimed that (i) a 0.7kb region from the first intron of CBX3 retains 
UCOE function when linked to a heterologous CMV promoter (Bandaranayake, 
Correnti et al. 2011), (ii) promoter-less CpG rich transgenes can establish a 
methylation-free DNA, open chromatin region in the absence of RNA polymerase II 
transcriptional activity (Thomson, Skene et al. 2010) and (iii) sub-fragments of CpG 
islands associated with developmentally regulated genes, including some lacking a 
promoter, retain their ability to maintain appropriate DNA methylation status in a 
transgene context (Lienert, Wirbelauer et al. 2011). Some of these observations 
clearly call into question the dual divergent transcription model of UCOE function 
(Allen and Antoniou 2007).  
 
The LV constructs Daedalus-F and Daedalus-R (Figure 4.3) were built to directly test 
the claim that a 0.7kb fragment from the first intron of CBX3 (Figure 4.1) can confer 
UCOE activity. Our results from transduced P19 and F9 cells both before and after 
differentiation down the neuroectodermal and endodermal lineages, respectively, 
clearly show that this element does not confer stability of expression on a linked 
SFFV promoter (Figures 4.4 - 4.7). Evidently, the reason for the apparent discrepancy 
between our results and published data appears to be due to the fact that previous 
claims of a UCOE capability for this 0.7kb CBX3 intronic fragment stem from 
transductions that gave rise to an average LV copy number per cell of 8-10 
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(Bandaranayake, Correnti et al. 2011). In this scenario only a single integrated vector 
copy remaining active in a given cell would allow it to score positive for GFP-
reporter gene expression and thus give the impression of functional stability. Indeed, 
the large (55%) drop in MFI observed in cells at 4 weeks post-transduction with the 
0.7UCOE-GFP (“Daedalus”) LV implies a large degree of vector silencing despite the 
apparent maintenance in numbers of GFP+ cells (Figure 4.2; (Bandaranayake, 
Correnti et al. 2011). Our results confirm that in all likelihood silencing of 0.7UCOE 
(Daedalus) vector expression is taking place. This is particularly evident in our 
experiments since they were designed to generate cells with a low (1-4) average 
vector copy number per cell (Figures 4.4C – 4.7C). In addition, the P19 and F9 
embryonal carcinoma cell lines we employ may represent a more sensitive and 
accurate functional gene silencing assay system (Zhang, Thornhill et al. 2007) 
(Zhang, Frost et al. 2010) than the CHO cells used previously (Bandaranayake, 
Correnti et al. 2011).  
 
The candidate 0.9UCOE-F and 0.9UCOE-R UCOEs were constructed based on a 
bioinformatics search of the A2UCOE region for certain (Sp1, CTCF, USF) 
transcription factor binding sites in an effort to identify a possible MDR (Lienert, 
Wirbelauer et al. 2011). The linking of this 0.9kb A2UCOE core region that spans 
both the HNRPA2B1 and CBX3 promoter/transcriptional start sites (Figure 4.1) to the 
SFFV promoter in the SEW vector (Figure 4.3), resulted in only a partial protection 
against silencing in both undifferentiated and differentiated P19 (Figures 4.8, 4.10, 
4.12) and F9 (Figures 4.9, 4.11, 4.13) cells. Thus, although the 0.9kb core A2UCOE 
promoter fragment may constitute an MDR, it does not retain a full UCOE capability 
unlike the larger 1.5kb A2UCOE, which extends further at both the HNRPA2B1 and 
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CBX3 ends. This difference in UCOE activity between these two A2UCOE core 
elements may be due the reduction in the length of the CpG island beyond a crucial 
point within the 0.9kb fragment such that it is unable to stably maintain its normally 
inherent open chromatin structure. 
 
The construction of the candidate 455UCOE, 527UCOE and 945UCOE LVs was 
based on the observation that CpG-rich DNA fragments devoid of promoter activity 
can establish an open chromatin structure in a transgene context (Thomson, Skene et 
al. 2010). The 455UCOE, 527UCOE and 945UCOE LVs contain fragments from the 
region immediately downstream of the two alternative first exons of CBX3, which 
possess the highest CpG density and also lack a promoter (Figure 4.1). It was 
therefore hypothesised that these 455bp, 527bp and 945bp fragments may be able to 
establish an open chromatin structure independent of promoter activity as previously 
suggested (Thomson, Skene et al. 2010) and confer stability on a linked SFFV 
promoter (Figure 4.3). Our results in both undifferentiated and differentiated P19 
(Figures 4.14, 4.16, 4.18) and F9 (Figures 4.15, 4.17, 4.19 and 15) cells clearly show 
that none of these CBX3-derived fragments are able to confer stability of expression 
and thus do not possess a UCOE capability. Indeed, the rate of reduction in 
expression was comparable between the SEW vector that contains the SFFV promoter 
alone, and those LVs with the linked 455UCOE, 527UCOE and 945UCOE elements 
(Figures 4.14A to 4.15A) demonstrating no UCOE activity for the 455bp and 527bp 




In conclusion, none of the novel candidate UCOE sub-fragments of the A2UCOE 
region either with (0.9UCOE-F, 0.9UCOE-R) or without (Daedalus-F, Daedalus-R; 
455UCOE, 527UCOE, 945UCOE) associated promoter activity retained a full UCOE 
capability. Only the 0.9UCOE-F and especially 0.9UCOE-R constructs that 
encompass the promoters and transcriptional start sites of HNRPA2B1 and CBX3 
possessed a significant but still partial ability to negate transgene silencing. Thus, 
despite published evidence to the contrary we were unable by these targeted 
experiments to identify an A2UCOE sub-region devoid of promoter activity that still 














Minimising the A2UCOE for 
direct transgene expression 








Results: Minimising the A2UCOE for direct transgene expression from the 
innate HNRPA2B1 promoter 
 
5.1 Introduction and background 
 
It has previously been shown that the innate HNRPA2B1 promoter of the 2.2kb 
A2UCOE (2.2A2UCOE; Figure 5.1) can provide stable transgene expression from 
both plasmid (Antoniou, Harland et al. 2003) and lentiviral (Zhang, Thornhill et al. 
2007) vectors. (See also, for example, Figures 4.8 and 4.9). As we failed to identify a 
CpG-rich A2UCOE sub-fragment either with or without associated promoter activity 
that fully retained UCOE function (Chapter 4), we next sought to determine if the 
2.2A2UCOE could be reduced in size but still retain full UCOE activity. In a 
previously published study it was shown that a 0.9kb A2UCOE (0.9A2UCOE; Figure 
5.1) again where transcription was directly from the HNRPA2B1promoter, did not 
provide stable expression in P19 cells transduced with an LV containing an 
0.9A2UCOE-eGFP cassette (Knight, Zhang et al. 2012). We, therefore, constructed 
LVs containing an A2UCOE-eGFP transgene deletion series between 2.2kb and 0.9kb 
in length (Figure 5.1). These vectors were tested for UCOE function in our standard 
murine embryonal carcinoma P19 and F9 cell assay system. The stability, potency, 
and reproducibility of expression of the eGFP transgene were analyzed in both 









Figure 5.1. Relative positions of the 2.2A2UCOE and sub-fragments analysed for 
UCOE activity. Upper panel: CpG density map and methylation-free CpG island. 
Middle panel: Positions of the two alternative first exons of CBX3 (green arrows) and 
the first exon of HNRPA2B1 (red arrow). Lower panel: positions of A2UCOE sub-
region fragments analysed for UCOE activity. 2.2A2UCOE: 2.2kb BamHI-Tth111I 
element. 1.7A2UCOE: 5’ deletion of the 2.2kb element to a HpaI site within the first 
intron of CBX3 to give a 1.7kb fragment. 1.2A2UCOE: further 5’ deletion of 
2.2A2UCOE element to a BsmBI site at the end of the alternative second exon of 
CBX3 to give a 1.2kb fragment. 0.9UCOE: 5’deletion sub-fragment of the 
2.2A2UCOE to a Csp45I site at the end of the alternative first exon of CBX3 to give a 
0.9kb fragment. Note: all fragments terminate at a Tth111I site 15bp from the end of 









5.2 LV used in this study 
 
The LV constructs SEW (SFFV-eGFP-WPRE) and 1.5A2UCOE-SEW are as 
previously described in Figures 3.1 and 4.3. The 2.2A2UCOE, 1.7A2UCOE, 
1.2A2UCOE and 0.9A2UCOE vectors are illustrated in Figure 5.2. 
Note: the 1.7A2UCOE and 1.2A2UCOE LVs were generated by Gautom Baruah and 
0.9A2UCOE vector was constructed by Thomas Broughton.    
 
 
Figure 5.2. Illustration of the 2.2A2UCOE deletion series lentiviral vectors. 
Top panel: A standard self-inactivating (SIN) lentiviral vector backbone containing a 
2.2kb A2UCOE (2.2A2UCOE) fragment with the innate HNRPA2B1 promoter 
driving expression of an enhanced green fluorescent protein (eGFP) reporter gene 
with downstream woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE). Lower panel: 5’ (CBX3 end) deletion series of the 2.2A2UCOE consisting 





The 2.2kb A2UCOE-eGFP cassette was generated by subcloning of the 2.2kb 
BamHI to Tth111I A2UCOE fragment (Figure 5.1; 2.2A2UCOE; Williams et 
al., 2005) in place of the SFFV promoter in the SEW LV backbone (Figure 5.2, 
top panel). The orientation of the 2.2A2UCOE is such that the HNRPA2B1 
promoter drives expression of the linked eGFP reporter gene. This 2.2A2UCOE 
LV has previously been shown to provide stable expression in P19 cell assays 
(Zhang, Frost et al. 2010).   
 
5.2.2. 1.7A2UCOE and 1.2A2UCOE 
 
The 1.7UCOE and 1.2UCOE constructs were generated by deleting the 
2.2A2UCOE to HpaI and BsmBI sites, respectively, at the CBX3 end of this 
element to give 1.7kb and 1.2kb sub-fragments (Figure 5.1). Again these are 
joined directly via the HNRPA2B1 promoter to an eGFP reporter gene to 




The 0.9A2UCOE construct was generated by a further deletion of the 
2.2A2UCOE element to a Csp45I site within the alternative first exon of CBX3 




5.3 Lentiviral vector titration in HEK293T cells 
 
Cells were collected for analysis by flow cytometry three days post-transduction 
of HEK293T cells with serial dilutions of viral stocks collected at both 2 and 3 
days post-transfection from each production run for all LVs: SEW (SFFV-
eGFP-WPRE), 1.5A2UCOE-SEW, 2.2A2UCOE, 1.7A2UCOE and 



















                          
                    Volume (µL) of viral vector stock 
2 µL 0.2 µL 0.02 µL 0.002 µL 
                                                     




 viral harvest 
SEW      72.45 / 61.43     12.23 / 10.12      2.5 / 1.22        0.54 / 0.23 
1.5A2UCOE-
SEW  
     78.48 / 66.2     16.8 / 11.18      3.5 / 2.14        0.82 / 0.51 
2.2A2UCOE      73.6 / 68.16     14.16 / 11.22      3.04 / 1.33        0.72 / 0.42 
1.7A2UCOE      71.1 / 63.44     12.05 / 8.12      2.04 / 1.02        0.6 / 0.12 
1.2A2UCOE       84.18 / 72.88     18.11 / 10.4      4.3 / 1.86 0.48 / 0.16 
 
Table 5.1. Titration of lentiviral vector (LV) preparations. A 2x10
5
 aliquots of 
HEK293T cells were transduced with 0.002-2 µL of a given LV stock from the first 
and second harvest of virus from culture supernatant during the time of preparation. 
Analysis of eGFP-positive cells at 3-days post-transduction was by flow cytometry. 







    5.3.1 Calculation of LV titre 
 
Viral titre (Table 5.2) was calculated based on the dilution of each harvest that 
gave a percentage of eGFP-positive cells between 1% and 10%. Pools of cells 
with percentages of eGFP-positive cells higher than 10% are very likely to 
contain multiple integrations of the vector, while very low scores could be false 
positives. 
 
On day one, 2x10
5
 293T cells were seeded in each 6-well. Thus, the percentage 
of eGFP-positive cells from flow cytometry analysis, reflects the percentage of 
the initial cell population that was successfully transduced and hence the 
number of infectious units added in the specified well. The dilution factor or the 
volume of the lentivirus preparation that was used is known, so the calculation 






























1.5A2UCOE-SEW  2.85 x 10
8
 1.96 x 10
8
 
2.2A2UCOE 2.35 x 10
8
 1.28 x 10
8
 





1.7A2UCOE 2.62 x 10
8




Table 5.2: Lentiviral vector (LV) titres. Viral titre as infectious units per ml 




 harvest of virus that 
gave a percentage of eGFP-positive HEK293T cells between 1% and 10% 












5.4 Functional assay of candidate UCOEs 1.2A2UCOE and 1.7A2UCOE in 
undifferentiated P19 and F9 cells  
 
P19 and F9 cells were transduced with the generated LVs at an MOI of 3 or 6, 
with the intention to start the experiment within the range of 40-60% eGFP-
positive cells in all pools. The transduced cells and negative control were then 
propagated in culture and assayed as a time course by flow cytometry, to 
determine the percentage of eGFP-positive cells and the mean fluorescence 
intensity (MFI) for each repeat transduction for each vector. Cell cultures were 
analysed every 7 days from day 3 post-transduction and extending to 45 days. 
Cell samples were taken at regular intervals for the flow cytometry analysis, to 
monitor the expression levels of the eGFP reporter gene. In addition, DNA was 
extracted from cells at each time point for RT-qPCR in order to determine the 
average vector copy number per cell.  
 
Figure 5.2A shows the flow cytometry time course results depicting percentage 
of eGFP+ cells. Although similar initial transduction efficiency was obtained 
with all vectors (45-60% eGFP+ cells), expression from the SEW (SFFV-eGFP-
WPRE), rapidly declined from 47% to 4% positive cells within 17 days. In 
contrast, the proportion of eGFP+ cells from the 1.5A2UCOE-SEW and 
2.2kbA2UCOE vectors remained completely stable over the 31-day period of 
culture. Therefore, whilst differences in the percentage of eGFP-positive cells 
transduced with 1.5A2UCOE-SEW and 2.2kbA2UCOE were significantly 
higher when compared with the results obtained for SEW and 1.2A2UCOE, the 
decrease of eGFP expression of the vector 1.2A2UCOE is parallel when 
compared with SEW. The expression of eGFP in SEW transduced cells had 
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dropped almost 80% after 2 weeks post-transduction. Similarly, with the 
exception of 1.5A2UCOE-SEW and 2.2kbA2UCOE, the reduction observed in 
eGFP-positive cells was 30% to 40% for 1.2A2UCOE over the same time 
period. However, the expression of eGFP in 1.7A2UCOE has remained stable 
over the same time period. The values of mean fluorescent intensity (MFI) for 
all vectors paralleled the eGFP expression results (Figure 5.2B). MFI was stable 
in the 1.5A2UCOE-SEW, 2.2kbA2UCOE and 1.7A2UCOE transduced cells, 




















































































Figure 5.2: Novel candidate UCOEs offer only partial protection against 
silencing in undifferentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE 1.2A2UCOE, 1.7A2UCOE and control SEW, 2.2kbA2UCOE 
and 1.5A2UCOE-SEW lentiviral vectors (Figure 3.1). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) 
cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector 
copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 31 days post-transduction. (A) timecourse of percentage eGFP-
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 


























Figure 5.3A shows the flow cytometry time course results depicting percentage 
of eGFP+ cells in undifferentiated F9 cells. The results show a parallel activity 
as with the P19 cells above. Although similar initial transduction efficiency was 
obtained with all vectors (39–50% eGFP+ cells), expression from the SEW 
(SFFV-eGFP-WPRE), rapidly declined from 45% to 5% positive cells within 17 
days. In contrast, the proportion of eGFP+ cells from the 1.5A2UCOE-SEW, 
2.2kbA2UCOE and 1.7A2UCOE vectors remained completely stable over the 
31-day period of culture. Therefore, whilst differences in the percentage eGFP-
positive cells transduced with 1.5A2UCOE-SEW, 2.2kbA2UCOE and 
1.7A2UCOE were significantly higher when compared with the results obtained 
for SEW and 1.2kb vectors, the decrease of eGFP expression of the vector 
1.2A2UCOE is slower when compared with SEW. The expression of eGFP in 
SEW transduced cells had dropped almost 80% after 2 weeks post-transduction. 
The values of mean fluorescent intensity (MFI) for all vectors paralleled the 
eGFP expression results (Figure 5.3B). MFI was stable in the 1.5A2UCOE-
SEW, 2.2kbA2UCOE and 1.7A2UCOE transduced cells, unstable in the case of 












































































Figure 5.3: Novel candidate UCOEs offer only partial protection against 
silencing in undifferentiated F9 cells. F9 cells were transduced with novel 
candidate UCOE 1.2A2UCOE, 1.7A2UCOE and control SEW, 2.2kbA2UCOE 
and 1.5A2UCOE-SEW lentiviral vectors (Figure 5.1). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) 
cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector 
copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 31 days post-transduction. (A) timecourse of percentage eGFP-
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 


























5.5 Functional assay of candidate UCOEs 1.2A2UCOE, 1.7A2UCOE in 
differentiated P19 and F9 cells  
 
The novel candidate UCOE vectors were able to confer partial stability of expression 
in undifferentiated P19 (Figure 5.4) and F9 (Figure 5.5) cells. We next evaluated the 
ability of these novel LVs to stabilize expression upon differentiation of P19 and F9 
cells down the neuroectodermal and endodermal lineages respectively.  
 
Cells transduced with each LV were first induced to form embryoid bodies in retinoic 
acid-containing differentiation medium via culture on non-adhesive plastic, which is a 
necessary pre-requisite state for later neuronal and endodermal differentiation. Cells 
subsequently differentiate into a mix of neuroectodermal and parietal endoderm cell 
types, of which fibroblast-like cells were the predominant type at the initial stage of 
differentiation (2-3 days after plating for P19 cells and 5-6 days for F9 cells), but with 
neurons and endoderm cells also present. The cultures were then enriched for non-
dividing cells by the application of 10 μM cytosine arabinoside, in which neurons and 
endoderm cells appear as the only survivors. The optimum incubation time to form 
embryoid bodies and to differentiate the cells into neuroectodermal and endoderm cell 
types was determined as 2-3 days for P19 cells and 5-6 days for F9 cells.  
 
The expression results from triplicate samples of cells transduced with the 
1.5A2UCOE-SEW, 2.2A2UCOE, 1.2A2UCOE, 1.7A2UCOE LVs following 
differentiation is presented in Figures 5.4 and 5.5. Our data from the differentiation 
experiments show that the control LVs carrying the UCOE construct (1.5A2UCOE-
SEW and 2.2A2UCOE) have remained stable after the P19 and F9 cells were 
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differentiated down the neuronal and endoderm lineages respectively (Figures 5.4A 
and 5.5A). Also. The 1.7A2UCOE vector has remained stable like the two A2UCOE 
control vectors (Figures 3.4A and 3.5A). However, the novel candidate UCOE vector 
1.2A2UCOE show a gradual reduction in eGFP expression whilst the silencing 
control SEW vector was rapidly repressed (Figures 5.4A and 5.5A).  
 
As in the case of undifferentiated cells (Figures 5.2 and 5.3), MFI values upon 
differentiation of both P19 and F9 cells paralleled the eGFP+ cell expression data 
(Figures 5.4B and 5.5B) whilst average vector copy number was essentially stable 
throughout the timecourse of the experiment (Figures 5.4C and 5.5C). 
 
Thus, the LVs tested in these experiments gave similar outcomes in undifferentiated 
and differentiated F9 and P19 cells. However, it is perhaps noteworthy that the rate of 
reduction in eGFP expression with the SEW and novel candidate UCOE 1.2A2UCOE 
LVs is greater upon differentiation (Figures 5.4A and 5.5A) than in undifferentiated 











































































Figure 5.4: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated P19 cells. P19 cells were transduced with novel 
candidate UCOE 1.2A2UCOE, 1.7A2UCOE and control SEW, 2.2kbA2UCOE 
and 1.5A2UCOE-SEW lentiviral vectors (Figure 5.1). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) 
cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector 
copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 45 days post-transduction. (A) timecourse of percentage eGFP-
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 





























































































Figure 5.5: Novel candidate UCOEs offer only partial protection against 
silencing in differentiated F9 cells. F9 cells were transduced with novel 
candidate UCOE 1.2A2UCOE, 1.7A2UCOE and control SEW, 2.2kbA2UCOE 
and 1.5A2UCOE-SEW lentiviral vectors (Figure 5.1). Cells were analysed by 
flow cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) 
cells, mean fluorescence intensity (MFI) and by RT-Q-PCR for average vector 
copy number (VCN) per cell. Data shows combined results from three 
independent transductions for each vector, plus negative control (NEG), over a 
period of 3 to 45 days post-transduction. (A) timecourse of percentage eGFP-
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 
(Mean + SEM, n=4; **p<0.01). (C) As in (A)/(B) but average VCN/cell; (Mean 





























5.6 Summary and Conclusions  
 
 
The primary aim of the experiments conducted in this phase of the project was 
to determine whether the novel candidate sub-fragment UCOEs 1.2A2UCOE 
and 1.7A2UCOE (Figure 5.1) confirm with the dual divergent transcription 
model of UCOE function and are able to confer stability of expression on a 
linked heterologous promoter. Although the 1.5kb A2UCOE-SEW and 2.2kb 
UCOE can confer stability of expression on a linked ubiquitous (Williams, 
Mustoe et al. 2005, Zhang, Frost et al. 2010) or tissue-specific (Talbot, 
Waddington et al. 2009, Brendel, Müller-Kuller et al. 2011) promoter it does so 
in an orientation specific manner with the CBX3 end of the element abutting the 
linked promoter. Our starting hypothesis was that this problem could be 
circumvented if both promoters of the selected gene pairs showed similar levels 
and variance of expression in a variety of tissues. That is the reason why 
uniformity of expression levels both across tissues but also in between the gene 
pair was taken into consideration. In this regard our results show that one of the 
sub-fragments of the candidate UCOEs 1.7A2UCOE is a good candidate to 
confer stability of expression (Figures 5.2 to 5.5).  
 
In this phase of the project P19 and F9 cells were successfully transduced with 
two novel candidate UCOEs as well as three control LVs. Stability and levels of 
expression of these vectors were analyzed in both undifferentiated and 
neuroectodermal and endodermal differentiated P19 and F9 cells, respectively. 
Our study has extended previous investigations, which only looked at 
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expression of UCOE-based LVs profiles in undifferentiated P19 cells (Yoon, 
Lee et al. 2009, Zhang, Frost et al. 2010).The results provide comparison of the 
previously reported results of the 1.5kb A2UCOE vectors in P19 cells as well as 
that of the control vectors. The eGFP expression of the candidate UCOE vector 
1.2A2UCOE decreased more rapidly than the 1.7A2UCOE. However, 
1.5A2UCOE-SEW, 2.2kb A2UCOE and 1.7A2UCOE gave perfectly stable 
expression over the course of our experiment, as before (Zhang, Frost et al. 
2010). Overall our results provide more evidence of the capacity of the 
A2UCOE, whether present in the configurations found in 1.5A2UCOE-SEW to 
provide stability and reproducibility of transgenes under the control of their 
innate HNRPA2B1 promoter or driven by a linked heterologous promoter such 
as SFFV whose activity is protected from silencing and positional effect 


















Functional analysis of the 
A2UCOE with direct transgene 
expression from the 
HNRPA2B1 promoter within 










Results: Functional analysis of the A2UCOE with direct transgene expression 
from the HNRPA2B1 promoter within murine ES cells 
 
6.1 Introduction and background 
 
It has previously been shown that the 1.5kb core A2UCOE and sub-fragments thereof, 
can confer stability of expression on linked heterologous ubiquitous (Pfaff, Lachmann 
et al. 2013)  (Ackermann, Lachmann et al. 2014) (Williams, Mustoe et al. 2005, 
Zhang, Frost et al. 2010) and tissue-specific (Müller-Kuller, Ackermann et al. 2015) 
promoters including within both embryonic and induced pluripotent stem cells and 
their differentiated progeny of all three germ layers. In Chapter 5 we showed that a 
1.7kb sub-fragment of the fully functional 2.2kb A2UCOE retained the ability for 
stable expression in undifferentiated P19 and F9 cells as well as upon differentiation 
of these embryonal carcinoma cell lines down the neuroectoderm and parietal 
endoderm lineages, respectively. However, it has not as yet been established as to 
whether the 2.2A2UCOE and now also the 1.7A2UCOE vectors, which drive 
transgene expression directly off the innate HNRPA2B1 promoter of this element, are 
also capable of stable expression in more physiological undifferentiated and 
differentiated murine embryonic stem (ES) cells. The aims of the experiments 
presented in this chapter were designed to test this possibility.    
 
Note: the experiments presented in this chapter were conducted collaboratively with 
Prof Agi Grigoriadis and Ms Ewa Kania, Department of Craniofacial Development 
and Stem Cell Biology, King's College London. 
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6.2 LV used in this study 
 
The LV constructs SEW (SFFV-eGFP-WPRE) and 1.5A2UCOE-SEW are as 
previously described in Chapter 3 (Figure 3.1). The 2.2A2UCOE, 1.7A2UCOE and 
1.2A2UCOE vectors are as described in Chapter 5 (Figure 5.2). In the interests of 


















Figure 6.1. Illustration of the novel candidate UCOE and control lentiviral 
vectors. A. SEW: self-inactivating (SIN) LV containing a spleen focus forming virus 
(SFFV) promoter driving expression of an enhanced green fluorescent protein (eGFP) 
reporter gene with downstream woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE). B. 1.5A2UCOE-SEW: 1.5kb core HNRPA2B1-CBX3 
UCOE (1.5A2UCOE) was inserted into a polylinker (PL) cloning site upstream of the 
SFFV promoter within SEW. C. 2.2A2UCOE-eGFP: 2.2kb HNRPA2B1-CBX3 UCOE 
(2.2A2UCOE) directly expressing a GFP reporter gene off the innate HNRPA2B1 
promoter. D, E. 1.7A2UCOE-eGFP and 1.2A2UCOE-eGFP: 5’ (CBX3 end) deletion 
series of the 2.2A2UCOE consisting of 1.7kb and 1.2kb sub-fragments. LTR: long 

















6.3 Lentiviral vector titration in HEK293T cells 
 
Cells were collected for analysis by flow cytometry three days post-transduction of 
HEK293T cells with serial dilutions of viral stocks collected at both 2 and 3 days 



















                          
                    Volume (µL) of viral vector stock 
2 µL 0.2 µL 0.02 µL 0.002 µL 
                                                     




 viral harvest 
SEW      84.15 / 62.45     15.12 / 11.24      4.2 / 1.66        0.92 / 0.44 
1.5A2UCOE-
SEW  
     72.22 / 61.35     13.11 / 10.22      3.7 / 1.55        0.71 / 0.35 
2.2A2UCOE      75.3 / 62.44     15.22 / 9.58      3.66 / 1.25        0.83 / 0.51 
1.7A2UCOE      68.55 / 61.21     14.12 / 8.45      3.01 / 1.11        0.62 / 0.14 
1.2A2UCOE       73.48 / 65.33     14.91 / 11.2      3.25 / 1.26 0.78 / 0.18 
 
Table 6.1. Titration of lentiviral vector (LV) preparations. A 2x10
5
 aliquot of 
HEK293T cells were transduced with 0.002-2 µL of a given LV stock from the first 
and second harvest of virus from culture supernatant during the time of preparation. 
Analysis of eGFP-positive cells at 3-days post-transduction was by flow cytometry. 






6.3.1 Calculation of LV titre 
 
Viral titre (Table 6.2) was calculated based on the dilution of each harvest that 
gave a percentage of eGFP-positive cells between 1% and 10%. Pools of cells 
with percentages of eGFP-positive cells higher than 10% are very likely to 
contain multiple integrations of the vector, while very low scores could be false 
positives. 
 
On day one, 2x10
5
 293T cells were seeded in each well. Thus, the percentage of 
eGFP-positive cells from flow cytometry analysis, reflects the percentage of the 
initial cell population that was successfully transduced and hence the number of 
infectious units added in the specified well. The dilution factor or the volume of 
the lentivirus preparation that was used is known, so the calculation of the 





















SEW 2.54 x 10
8







 1.46 x 10
8
 
2.2A2UCOE 2.73 x 10
8
 1.36 x 10
8
 





1.2A2UCOE  2.11 x 10
8




Table 6.2. Lentiviral vector (LV) titres. Viral titre as infectious units per ml 




 harvest of virus that 
gave a percentage of eGFP-positive HEK293T cells between 1% and 10% 









6.4 Functional assay of candidate 1.2A2UCOE and 1.7A2UCOE LVs in 
undifferentiated murine ES cells 
 
Murine ES cells were transduced with the generated LVs at an MOI of 3, with 
the intention to start the experiment within the range of 40-60% eGFP-positive 
cells in all pools. The transduced cells and untransduced negative controls were 
then propagated and assayed as a time course by flow cytometry to determine 
the percentage of eGFP-positive cells and mean fluorescence intensity (MFI) for 
each repeat transduction for each vector. Cell cultures were analysed every 7 
days from day 3 post-transduction and extending to 31 days. In addition, DNA 
was extracted from cells at each time point for qPCR analysis in order to 
determine the average VCN per cell.  
 
Figure 6.2A shows the flow cytometry time course results depicting percentage 
of eGFP+ cells. Initial transduction efficiency was between 45-52% eGFP+ 
cells in all cases. However, expression from SEW rapidly declined from 48% to 
5% eGFP+ cells within 17 days. In contrast, the proportion of eGFP+ cells from 
the 1.5A2UCOE-SEW and 2.2A2UCOE vectors remained completely stable 
over the 31-day period of culture. The 1.7A2UCOE LV displayed the same 
stable pattern of expression to that seen with the 2.2A2UCOE vector over the 
time course of the experiment. By comparison, the percentage of eGFP+ cells 
transduced with the 1.2A2UCOE construct decreased over time although much 
more gradually than that seen with SEW. The expression of eGFP in SEW 
transduced cells dropped by almost 80% after 2 weeks post-transduction 
whereas the percentage of eGFP-positive cells decreased by only 30% to 40% in 
the case of the 1.2A2UCOE vector over the same time period. The values of 
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mean fluorescent intensity (MFI) for all vectors paralleled the eGFP expression 
results (Figure 6.2B). MFI was stable in the 1.5A2UCOE-SEW, 2.2A2UCOE 
and 1.7A2UCOE transduced cells and unstable in the case of SEW and 
1.2A2UCOE. Finally, average VCN per cell was unaltered during the course of 
the experiment clearly demonstrating that loss of expression from the SEW and 

















































































Figure 6.2. The 2.2A2UCOE and 1.7A2UCOE offer complete protection 
against silencing in undifferentiated murine ES cells. Murine ES cells were 
transduced with the 2.2A2UCOE, 1.7A2UCOE, 1.2A2UCOE and control SEW 
and 1.5A2UCOE-SEW LVs (Figure 6.1). Cells were analysed by flow 
cytometry to detect percentage of eGFP reporter gene expressing (eGFP+) cells, 
mean fluorescence intensity (MFI) and by qPCR for average vector copy 
number (VCN) per cell. Data shows combined results from three independent 
transductions for each vector, plus negative control (NEG), over a period of 3 to 
31 days post-transduction. (A) timecourse of percentage eGFP-positive cells; 
(Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; (Mean + SEM, 

























6.5 Functional analysis of 2.2A2UCOE, 1.7A2UCOE and 1.2A2UCOE 
vectors in differentiated murine ES cells  
 
The 2.2A2UCOE and 1.7A2UCOE vectors displayed complete stability of expression 
in undifferentiated ES cells (Figure 6.2). We next sought to determine if these LVs 
retained their capability for stable expression upon differentiation of these cells. ES 
cells were transduced with the 2.2A2UCOE, 1.7A2UCOE and 1.2A2UCOE series of 
vectors and cultured under non-adhesive conditions on uncoated bacterial Petri dishes 
to induce embryoid body formation, which would contain cell types representative of 
all three germ layers. Analysis by flow cytometry to determine percentage eGFP+ 
cells and MFI was conducted on the cell cultures prior to induced embryoid body 
differentiation at 3-days post-transduction and at day 10 and 17 following 
differentiation. The results (Figure 6.3) show that the 2.2A2UCOE and 1.7A2UCOE 
vectors essentially retain the same level of eGFP+ cells (Figure 6.3A) and MFI 
(Figure 6.3B) up to the 17 day period of the experiment. In contrast, expression from 
the 1.2A2UCOE LV declined over time, reducing to approximately 40% of eGFP+ 
starting values by day 17 with a parallel drop in MFI. Thus, by these preliminary 
results the expression profile seen with the 2.2A2UCOE, 1.7A2UCOE and 
1.2A2UCOE LVs in embryoid body differentiated ES cells was similar to that seen in 
undifferentiated cells (Figure 6.2); that is, the 2.2A2UCOE and 1.7A2UCOE vectors 
retained stability of expression whilst the function of the 1.2A2UCOE was unstable 






























































Figure 6.3. The 2.2A2UCOE and 1.7A2UCOE vectors but not the 
1.2A2UCOE construct retain stability of expression following murine ES 
cell differentiation to embryoid bodies. Murine ES cells were transduced with 
the 2.2A2UCOE, 1.7A2UCOE and 1.2A2UCOE LVs (Figure 6.1) and at 3-days 
post-transduction transferred to differentiation medium in non-adherent 
uncoated bacterial Petri dishes to induce embryoid body formation. Cells were 
analysed prior to (day 3) and after (days 10 and 17) induced embryoid body 
differentiation by flow cytometry to measure percentage of eGFP reporter gene 
expressing (eGFP+) cells and mean fluorescence intensity (MFI). Data shows 
combined results from three independent transductions for each vector, plus 
negative (untransduced) control (NEG). (A) timecourse of percentage eGFP-
positive cells; (Mean + SEM, n=4; **p<0.01). (B) As in (A) but showing MFI; 

















6.6 Summary and Conclusions  
 
The aim of this phase of the project was to evaluate whether A2UCOE-based 
LVs where the gene of interest is transcribed directly off the innate HNRPA2B1 
promoter, retain stability of expression in undifferentiated and embryoid body 
differentiated murine ES cells. To this end ES cells were transduced and 
analysed with the 2.2A2UCOE, 1.7A2UCOE and 1.2A2UCOE vectors (Figure 
6.1). 
 
Our results clearly show that as in the case for these vectors in murine P19 and 
F9 embryonal carcinoma cells (see Chapter 3), the 2.2A2UCOE and 
1.7A2UCOE constructs retained a full capability for stable expression in 
undifferentiated ES cells (Figure 6.2). In contrast the 1.2A2UCOE vector 
retained at best only partial stability of expression although at a significantly 
superior level to that of the SFFV-based SEW silencing control LV. Preliminary 
results in ES cells induced to undergo differentiation to embryoid bodies, which 
contain cells representative of all three germ layers, also suggest that 
2.2A2UCOE and 1.7A2UCOE but not 1.2A2UCOE retain their capability for 
stable expression (Figure 6.3). 
 
These data represent the first evidence that A2UCOE-based LV constructs with 
expression off the innate HNRPA2B1 promoter provide reproducible and stable 
expression within undifferentiated and differentiated ES cells. Thus, vectors 
employing the 1.7A2UCOE-driven transgenes can be considered as very good 
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candidates for research and therapeutic purposes where reproducible and long-
term stability of expression is required when targeting ES cells and their 






































The integrating gammaretroviral and lentiviral class of vectors remain the best option 
for achieving stable retention and expression of a therapeutic gene. This is especially 
the case when targeting mitotic stem cell populations. Indeed, over the 15 years we 
have seen successful outcomes in clinical trials using these classes of vectors 
targeting HSCs via an ex vivo approach. Severe combined immunodeficiency disease 
(SCID), particularly SCID-X1, SCID-ADA (Cavazzana-Calvo, Fischer et al. 2012, 
Cavazza, Moiani et al. 2013) and Wiskott-Aldrich syndrome (WAS) and chronic 
granulomatous disease (CGD) ((Ott, Seger et al. 2007, Aiuti, Bacchetta et al. 2012) 
have been successfully treated by genetic augmentation of the patient’s HSC with 
gammaretroviral vectors. More recently, LVs have been successfully employed to 
treat the inherited demyelinating conditions X-(Cartier, Hacein-Bey-Abina et al. 
2009) and MLD (Biffi, Montini et al. 2013) as well as WAS (Bosticardo, Ferrua et al. 
2014).  
 
However, one is faced with two problems that always need to be addressed when 
using these integrating classes of viral vectors. First, insertional mutagenesis and 
second epigenetic-mediated therapeutic transgene silencing (Antoniou, Skipper et al. 
2013).   The problem of insertional mutagenesis by gammaretroviral integration 
causing inadvertent upregulation of host cell proto-oncogenes and oncogenesis, was 
observed in 5 out of a total of 20 patients treated for SCID-X1 (Cavazzana-Calvo, 
Fischer et al. 2012, Cavazza, Moiani et al. 2013). Transgene silencing by promoter 
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DNA methylation ultimately led to failure of initially successful gene therapy in two 
CGD patients (Ott, Seger et al. 2007, Aiuti, Bacchetta et al. 2012). 
 
The overall theme of this thesis is concerned with addressing the problem of silencing 
of LV-delivered therapeutic transgenes by the use of ubiquitous chromatin opening 
elements (UCOEs). The UCOE from the human HNRPA2B1-CBX3 housekeeping 
gene locus (A2UCOE) has now seen extensive use within LVs, which has 
demonstrated its ability to provide unprecedented reproducible and stable transgene 
expression in vivo especially when targeting stem cell populations (Antoniou, Skipper 
et al. 2013).    
 
The proposed mechanism by which the A2UCOE is able to confer both 
reproducibility and stability of expression independent of the site of transgene 
integration, consists of two components; a region of extended CpG methylation-free 
region coupled with divergent transcription with an inherent chromatin opening 
capability from the HNRPA2B1 and CBX3 promoters (Allen and Antoniou 2007). The 
aim of the work conducted under this thesis was to functionally investigate these 
proposed mechanisms of action. Ultimately it was hoped to identify a minimal, fully 
functional A2UCOE for incorporation within LVs thereby maximising space for the 






7.1 Novel candidate SETD3-CCNK and artificial RPS11-HNRPA2B1 dual 
divergent transcriptional elements possess only a partial UCOE 
function 
 
It has previously been reported that the placement of the core 1.5kb or 1.2kb 
A2UCOE upstream of heterologous promoters would confer stability of expression in 
an orientation specific manner; that is, when the CBX3 end of the A2UCOE was 
placed next to the heterologous ubiquitous SFFV (Zhang, Frost et al. 2010) and EF1 
(Pfaff, Lachmann et al. 2013) promoters or tissue-specific MRP8 (Brendel, Müller-
Kuller et al. 2012) promoter. The reason put forward to try and explain this 
orientation-bias in A2UCOE function was because the relatively weak transcriptional 
activity of the CBX3 promoter compared to that of HNRPA2B1. Thus, divergent 
transcription from the stronger HNRPA2B1 promoter would provide a better barrier 
against repressive epigenetic (DNA methylation, histone modification) processes 
spreading into the transgene region and thus silencing expression. Our first series of 
experiments were designed to test this hypothesis by seeking to identify and construct 
UCOEs with a dual divergent transcriptional configuration but which may function 
equally in either orientation when linked to heterologous promoters. Our starting 
hypothesis was that any problem in orientation bias in UCOE-heterologous promoter 
combination function could be circumvented if both promoters of the selected gene 
pairs showed similar levels and variance of expression between tissues.  
 
The first novel candidate UCOE selected was the SETD3-CCNK housekeeping gene 
pair as these two dual divergently transcribed pair of genes are both relatively 
uniformly expressed across 40 different human tissues and cell types (She, Rohl et al. 
2009). In order to directly test the hypothesis that the orientation bias of the A2UCOE 
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when linked to heterologous promoters was due to the weak transcriptional activity of 
CBX3, an artificial UCOE was constructed whereby the CBX3 component of the 
A2UCOE was replaced with the single promoter-CpG island of the RPS11 
housekeeping gene but still in a divergently transcribing configuration. The RPS11 
element was again chosen as this gene is expressed at a uniformly high level across 
different human tissues (She, Rohl et al. 2009).  
 
These novel candidate UCOE SETD3-CCNK and RPS11-HNRPA2B1 elements were 
linked upstream of the highly silencing-prone SFFV promoter (Figure 3.1) to evaluate 
their ability to prevent repression of this element in undifferentiated and differentiated 
P19 and F9 cells. In one respect the results we obtained are encouraging in that both 
orientations of the SETD3-CCNK element (SET-CCN-SEW, CCN-SET-SEW) and 
the artificial HNRPA2B1-RPS11 combination (B1-RPS-SEW, RPS-B1-SEW) showed 
similar abilities to confer stability of expression from the SFFV promoter independent 
of orientation in both cell lines and all conditions (Figures 3.4, 3.6, 3.8, 3.10). 
However, our results also show that neither the SETD3-CCNK nor the HNRPA2B1-
RPS11 elements were as effective as the prototypical 1.5A2UCOE at negating 
silencing of the linked SFFV promoter. The 1.5A2UCOE-SEW construct gave 
perfectly stable expression over the course of our experiment in not only 
undifferentiated P19 cells as previously reported (Zhang, Frost et al. 2010), but also in 
F9 cells. Furthermore, the 1.5A2UCOE-SEW vector maintained stable expression 
upon neuroectodermal and endodermal differentiation of P19 and F9 cells, 
respectively. Overall, our results from these experiments provided further evidence of 
the potent capacity of the A2UCOE present in the configuration found in 
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1.5A2UCOE-SEW LV to provide stability and reproducibility of transgene 
expression when linked to a heterologous promoter such as SFFV. 
 
7.2 Sub-regions of the A2UCOE fail to retain function 
 
A number of publications have questioned the need for divergent or even any 
associated promoter activity for UCOE function. Bandarayake and colleagues claimed 
that a 700bp fragment from the 3’ end of intron I of CBX3 (Figure 4.1, 0.7UCOE), 
and thus devoid of promoter activity, was able to confer stability of expression on a 
linked CMV-GFP reporter construct from within an LV context in CHO cells albeit at 
high (8-10) average vector copies per cell (Bandaranayake, Correnti et al. 2011). We 
thus sought to test this same 0.7UCOE “Daedalus” element within our standard assay 
system by placement upstream of the SFFV promoter in forward and reverse 
orientations within the SEW LV (Figure 4.3; Daedalus-F, Daedalus-R) and functional 
analysis in P19 and F9 cells. Our results (Figures 4.4-4.7) clearly show that this 
Daedalus 0.7UCOE was unable to confer stability of expression on the linked SFFV 
promoter in either orientation in both undifferentiated and differentiated P19 and F9 
cells. It was clear from our results that the reason for apparent stability of expression 
seen in CHO cells was due to the high average vector copy number per cell and that 
most integration events were in fact being silenced as evidenced by the dramatic drop 
in MFI at 14 days post-transduction (Bandaranayake, Correnti et al. 2011). These data 
demonstrate the importance of evaluating stability of expression from LVs at low 
vector copy per cell otherwise misleading results may be obtained, especially when 




A report by Thomson and colleagues (Thomson, Skene et al. 2010) suggested that 
transgenes consisting of a CpG-rich DNA fragment but lacking a promoter are 
sufficient to establish a methylation-free region with associated active histone 
modification marks in the absence of RNA polymerase II. Based on these findings, 
we sought to analyse the most CpG dinucleotide dense sub-regions of the A2UCOE, 
especially those lacking either the HNRPA2B1 or CBX3 promoters, for UCOE 
function. The most CpG-dense region of the A2UCOE CpG island lies within the first 
intron of CBX3 immediately downstream of the two alternative first exons (Figure 
4.1; 945UCOE, 527UCOE, 455UCOE) and was thus chosen for functional analysis. 
This 945bp region was divided into two sub-fragments of 455bp and 527bp and all 
three linked individually upstream of the SFFV promoter within the SFFV-eGFP 
(SEW) vector (Figure 4.3; 945UCOE, 527UCOE, 455UCOE). Our results show that 
despite the very high CpG density of these fragments, none of them were able to 
confer stability of expression on the linked SFFV promoter in both undifferentiated 
and differentiated P19 and F9 cells (Figures 4.14-4.19). Thus, CpG density alone is 
clearly not sufficient to establish a methylation-free open chromatin structure and that 
some other feature or features are also required. The missing component can of course 
be the lack of associated promoter and transcriptional activity with the 945UCOE, 
527UCOE and 455UCOE elements. Alternatively, the length of the CpG island region 
may have been reduced below a critical length required for it to maintain its 
methylation-free, open chromatin and transcriptionally permissive structure (Allen 
and Antoniou 2007).      
 
It has also been reported that sub-fragments of CpG islands associated with the 
promoters of developmentally regulated genes retain their ability to maintain 
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appropriate DNA methylation status in a transgene context (Lienert, Wirbelauer et al. 
2011). This included some CpG island sub-fragments that lacked their cognate 
promoter region and gave rise to them being designated as “methylation-determining 
regions” (MDRs). Based on these interesting observations we decided to ascertain if a 
similar MDR was present in the housekeeping gene region of the A2UCOE. A 
candidate MDR within the A2UCOE region was initially sought by a bioinformatics 
investigation for key transcription factor  (Sp1, CTCF, USF) binding sites that are 
thought to constitute an MDR signature (Lienert, Wirbelauer et al. 2011). This 
revealed a 0.9kb core fragment extending from the first exons of CBX3 and 
HNRPA2B1 and thus including both promoter regions as being a possible MDR (data 
not shown). As in previous experiments, we linked the 0.9kb core A2UCOE region 
encompassing the hypothetical MDR (Figure 4.1; 0.9UCOE) upstream of the SFFV 
promoter within the SEW LV (Figure 4.3; 0.9UCOE-F and 0.9UCOE-R) to test its 
ability to confer stability of expression in our proven differentiated and 
undifferentiated P19 and F9 cell assay. Our results show that the MDR candidate 
0.9kb A2UCOE region is able to confer significant but still partial protection against 
silencing of the linked SFFV promoter when compared to the larger 1.5A2UCOE core 
fragment in both undifferentiated and differentiated P19 (Figures 4.8, 4.10, 4.12) and 
F9 (Figures 4.9, 4.11, 4.13) cells. Thus, although the 0.9kb core A2UCOE promoter 
fragment may constitute an MDR, it does not retain a full UCOE capability as does 
the larger 1.5kb A2UCOE, which extends further at both the HNRPA2B1 and CBX3 
ends. As in the case of the 945UCOE, 527UCOE and 455UCOE fragments, this 
difference in UCOE activity between these two A2UCOE core elements may be due 
the reduction in the length of the CpG island beyond a crucial point within the 0.9kb 
fragment such that it is unable to stably maintain its normally inherent open chromatin 
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structure (Allen and Antoniou 2007). Alternatively, binding sites for additional 
transcription factors that are crucial for UCOE function may have been deleted in 
reducing A2UCOE length from 1.5kb to 0.9kb.    
 
In conclusion, none of the novel candidate UCOE sub-fragments of the A2UCOE 
region either with (0.9UCOE-F, 0.9UCOE-R) or without (Daedalus-F, Daedalus-R; 
455UCOE, 527UCOE, 945UCOE) associated promoter activity retained a full UCOE 
capability. Only the 0.9UCOE-F and especially 0.9UCOE-R constructs that 
encompass the promoters and transcriptional start sites of HNRPA2B1 and CBX3 
possessed a significant but still partial ability to negate transgene silencing. Thus, 
despite published evidence to the contrary we were unable by these targeted 
experiments to identify an A2UCOE sub-region devoid of promoter activity that still 
retained a full UCOE function.  
 
7.3 A 1.7kb sub-fragment of the 2.2kb A2UCOE retains full activity 
 
Prior to the commencement of this project it had been shown that the innate 
HNRPA2B1 promoter of the 2.2kb A2UCOE (2.2A2UCOE; Figure 5.1) can provide 
stable transgene expression from both plasmid (Antoniou, Harland et al. 2003) and 
lentiviral (Zhang, Thornhill et al. 2007) vectors. (See also, for example, Figures 4.8 
and 4.9). In contrast, a 0.9kb A2UCOE (0.9A2UCOE; Figure 5.1) again where 
transcription was directly from the HNRPA2B1promoter, did not provide stable 
expression in P19 cells transduced with a LV containing a 0.9A2UCOE-eGFP 
cassette (Knight, Zhang et al. 2012). We, therefore, investigated as to whether lengths 
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of the A2UCOE between the 2.2A2UCOE and 0.9A2UCOE constructs retained full 
activity. This entailed building deletion constructs of 1.7kb and 1.2kb of the 
2.2A2UCOE (Figure 5.1) and linkage to an eGFP reporter gene with expression from 
the HNRPA2B1 promoter (Figure 5.2). These vectors were tested for UCOE function 
in our standard murine embryonal carcinoma P19 and F9 cell assay system with 
stability, potency, and reproducibility of expression of the eGFP transgene were 
analyzed both before and after differentiation.  
 
Our results clearly show that the 1.7A2UCOE but not the 1.2A2UCOE construct 
provides comparable stability of expression to that of the full 2.2A2UCOE in both 
undifferentiated and differentiated P19 (Figures 5.3, 5.5, 5.7) and F9 (Figures 5.4, 5.6, 
5.8) cells. We also showed that the smaller 0.9A2UCOE fragment previously shown 
not to retain stability of expression in undifferentiated P19 cells (Knight, Zhang et al. 
2012), is also incapable of stable expression in undifferentiated F9 cells and in both 
differentiated P19 and F9 cells. 
 
The inability of the 1.2A2UCOE and 0.9A2UCOE vectors to maintain stability of 
expression is despite that fact that both constructs retain a dual CBX3-HNRPA2B1 
divergently transcribed promoter configuration (Figure 5.1). In addition, our finding 
of instability of expression from the 1.2A2UCOE appears at odds with those of 
Müller-Kuller and colleagues (Müller-Kuller, Ackermann et al. 2015). They reported 
that a 0.7kb sub-fragment of the A2UCOE encompassing just the CBX3 promoter and 
alternative first exons (designated as “CBX3-UCOE”), is capable of driving stable 
albeit very low levels of transcription and also able to stabilise expression from linked 
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heterologous SFFV and MRP8 promoters in P19, ES, HSC cells and derivatives. 
However, as the 0.7kb CBX3-UCOE constitutes the CBX3 half and, therefore, a 
continuous part of the 1.2A2UCOE, it would be expected that expression from the 
naturally associated HNRPA2B1 promoter would also be stabilised, which is clearly 
not the case in P19 (Figures 5.3, 5.5, 5.7), F9 (Figures 5.4, 5.6, 5.8) and ES (Figures 
6.2 and 6.3) cells. The difference, of course, between our 1.2A2UCOE and the CBX3-
UCOE-SFFV/MRP8 constructs tested by Müller-Kuller and colleagues, is that the 
direction of transcription of CBX3 in 1.2A2UCOE is divergent to HNRPA2B1 (Figure 
6.1) whereas it is in the same direction in the case of both CBX3-UCOE-SFFV and 
CBX3-UCOE-MRP8 (Müller-Kuller, Ackermann et al. 2015). At face value these 
observations clearly question the requirement for divergent transcription for A2UCOE 
function although further experiments involving, for example reversing the 
orientation of the 0.7kb CBX3-UCOE region within the 1.2A2UCOE construct, are 
required to address the molecular basis of this discrepancy.                             
 
What our results with the 1.7A2UCOE and 1.2A2UCOE constructs suggest is that 
elements and/or functions in addition to divergent transcription are required for full 
A2UCOE function and that these are lost upon deletion of the 500bp CBX3 region 
between the 1.7kb and 1.2kb endpoints of the 1.7A2UCOE and 1.2A2UCOE 
constructs. What these elements and processes might be is currently unknown but 
could include either deletion of crucial transcription factor binding sites or reduction 





7.4 The 2.2A2UCOE and 1.7A2UCOE vectors retain full UCOE activity in 
murine embryonic stem cells 
 
Given that the 1.7kb sub-fragment of the fully functional 2.2kb A2UCOE retained the 
ability for stable expression in undifferentiated and differentiated P19 and F9 cells 
(see Chapter 5), we also evaluated as to whether the 2.2A2UCOE and 1.7A2UCOE 
vectors are also capable of stable expression in more physiological undifferentiated 
and differentiated murine ES cells. Our results clearly show that both the 
2.2A2UCOE and 1.7A2UCOE constructs retained a full capability for stable 
expression in undifferentiated and embryoid body differentiated ES cells (Figures 6.2 
and 6.3). In contrast the 1.2A2UCOE vector retained at best only partial stability of 
expression although at a significantly superior level to that of the SFFV-based SEW 
silencing control LV (Figures 6.2 and 6.3). These data represent the first evidence that 
A2UCOE-based LV constructs with expression off the innate HNRPA2B1 promoter 
provide reproducible and stable expression within undifferentiated and differentiated 
ES cells. 
 
In summary, attempts in this project to identify and construct novel dual divergently 
transcribed promoter elements to match the UCOE capability of A2UCOE were only 
partially successful. In addition, a functional dissection of the A2UCOE by deletion 
analysis of the fully functional element failed to identity any sub-fragments that were 
CpG rich but devoid of one or both of the HNRPA2B1 and CBX3 promoters, which 
retained UCOE function. Only a 0.9kb core fragment spanning both CBX3 and 
HNRPA2B1 promoters was found to be significantly but partially protective against 
transcriptional silencing. Finally, we successfully reduced the size of fully functional 
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A2UCOE designed for expression off the innate HNRPA2B1 promoter to 1.7kb, 
reduction of 500bp over the previous best of 2.2kb.   
 
Overall, our results do not dispute the two component model of A2UCOE function 
(dual divergent transcription from within an extended CpG island). In addition, from a 
practical perspective our finding that the 1.7A2UCOE retains the same stability of 
expression as the larger 2.2A2UCOE element suggests that it can effectively replace 
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